Acadia Healthcare (ACHC) 10-Q 29 Apr 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 29, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	ACHC
Entity Registrant Name	Acadia Healthcare Company, Inc.
Entity Central Index Key	1,520,697
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		87,427,576

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 36,582	$ 11,215
Accounts receivable, net of allowance for doubtful accounts of $32,565 and $29,332, respectively	276,880	216,626
Other current assets	79,803	66,895
Total current assets	393,265	294,736
Property and equipment, net	3,337,765	1,709,053
Goodwill	2,771,365	2,128,215
Intangible assets, net	102,593	59,575
Deferred tax assets - noncurrent	41,753	49,114
Other assets	49,618	38,515
Total assets	6,696,359	4,279,208
Current liabilities:
Current portion of long-term debt	69,223	45,360
Accounts payable	118,210	91,341
Accrued salaries and benefits	112,714	80,696
Other accrued liabilities	108,663	72,806
Total current liabilities	408,810	290,203
Long-term debt	3,497,569	2,195,384
Deferred tax liabilities - noncurrent	94,882	23,936
Other liabilities	124,492	78,602
Total liabilities	4,125,753	2,588,125
Redeemable noncontrolling interests	$ 7,736	$ 8,055
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 and 90,000,000 shares authorized at March 31, 2016 and December 31, 2015, respectively; 86,539,997 and 70,745,746 issued and outstanding as of March 31, 2016 and December 31, 2015, respectively	$ 865	$ 707
Additional paid-in capital	2,475,383	1,572,972
Accumulated other comprehensive loss	(153,062)	(104,647)
Retained earnings	239,684	213,996
Total equity	2,562,870	1,683,028
Total liabilities and equity	$ 6,696,359	$ 4,279,208

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Receivable, allowance for doubtful accounts	$ 32,565	$ 29,332
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	90,000,000
Common stock, shares issued	86,539,997	70,745,746
Common stock, shares outstanding	86,539,997	70,745,746

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenue before provision for doubtful accounts	$ 627,183	$ 374,158
Provision for doubtful accounts	(10,370)	(8,375)
Revenue	616,813	365,783
Salaries, wages and benefits (including equity-based compensation expense of $6,956 and $3,894, respectively)	341,028	205,871
Professional fees	39,991	22,427
Supplies	26,685	16,254
Rents and leases	14,806	5,886
Other operating expenses	70,247	40,527
Depreciation and amortization	27,975	13,104
Interest expense, net	37,714	22,146
Gain on foreign currency derivatives	(410)	(53)
Transaction-related expenses	26,298	18,416
Total expenses	584,334	344,578
Income from continuing operations before income taxes	32,479	21,205
Provision for income taxes	7,110	6,613
Income (loss) from continuing operations	25,369	14,592
Income from discontinued operations, net of income taxes		2
Net income	25,369	14,594
Net loss attributable to noncontrolling interests	319
Net income attributable to Acadia Healthcare Company, Inc.	$ 25,688	$ 14,594
Basic earnings attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations	$ 0.31	$ 0.23
Income from discontinued operations	0	0
Net income	0.31	0.23
Diluted earnings attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations	0.31	0.23
Income from discontinued operations	0	0
Net income	$ 0.31	$ 0.23
Weighted-average shares outstanding:
Basic	82,943	62,530
Diluted	83,420	62,894

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Income (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Equity-based compensation expense	$ 6,956	$ 3,894

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 25,369	$ 14,594
Other comprehensive loss:
Foreign currency translation loss	(48,415)	(29,389)
Other comprehensive loss	(48,415)	(29,389)
Comprehensive loss	(23,046)	(14,795)
Comprehensive loss attributable to noncontrolling interests	319
Comprehensive loss attributable to Acadia Healthcare Company. Inc.	$ (22,727)	$ (14,795)

Condensed Consolidated Stateme7

Condensed Consolidated Statement of Equity (Unaudited) - 3 months ended Mar. 31, 2016 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2015	$ 1,683,028	$ 707	$ 1,572,972	$ (104,647)	$ 213,996
Balance, shares at Dec. 31, 2015	70,745,746	70,746,000
Common stock issued under stock incentive plans	$ 109	$ 3	106
Common stock issued under stock incentive plans, shares	7,075	260,000
Common stock withheld for minimum statutory taxes	$ (6,787)		(6,787)
Equity-based compensation expense	6,956		6,956
Excess tax benefit from equity awards	0	$ 0	0	0	0
Issuance of common stock, net	901,979	$ 155	901,824
Issuance of common stock, net, shares		15,534,000
Other comprehensive loss	(48,415)			(48,415)
Other	312		312
Net income attributable to Acadia Healthcare Company, Inc.	25,688				25,688
Balance at Mar. 31, 2016	$ 2,562,870	$ 865	$ 2,475,383	$ (153,062)	$ 239,684
Balance, shares at Mar. 31, 2016	86,539,997	86,540,000

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities:
Net income	$ 25,369	$ 14,594
Adjustments to reconcile net income to net cash provided by continuing operating activities:
Depreciation and amortization	27,975	13,104
Amortization of debt issuance costs	2,147	1,468
Equity-based compensation expense	6,956	3,894
Deferred income tax expense	9,085	19,224
Income from discontinued operations, net of taxes		(2)
Gain on foreign currency derivatives	(410)	(53)
Other	882	378
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	(3,749)	(6,957)
Other current assets	(8,075)	(23,758)
Other assets	(2,402)	(636)
Accounts payable and other accrued liabilities	7,498	1,274
Accrued salaries and benefits	(6,347)	(5,022)
Other liabilities	354	580
Net cash provided by continuing operating activities	59,283	18,088
Net cash (used in) provided by discontinued operating activities	(619)	134
Net cash provided by operating activities	58,664	18,222
Investing activities:
Cash paid for acquisitions, net of cash acquired	(580,096)	(49,618)
Cash paid for capital expenditures	(90,089)	(52,879)
Cash paid for real estate acquisitions	(14,799)	(1,722)
Settlement of foreign currency derivatives	745
Other	(1,208)	(383)
Net cash used in investing activities	(685,447)	(104,602)
Financing activities:
Borrowings on long-term debt	1,480,000	875,000
Borrowings on revolving credit facility	58,000	93,000
Principal payments revolving credit facility	(166,000)
Principal payments on long-term debt	(13,669)	(7,938)
Repayment of assumed debt	(1,348,389)	(904,467)
Payment of debt issuance costs	(34,167)	(22,191)
Issuance of common stock, net	685,097
Common stock withheld for minimum statutory taxes, net	(6,679)	(5,110)
Excess tax benefit from equity awards		4,310
Other	(224)
Net cash provided by financing activities	653,969	32,604
Effect of exchange rate changes on cash	(1,819)	(2,232)
Net increase (decrease) in cash and cash equivalents	25,367	(56,008)
Cash and cash equivalents at beginning of the period	11,215	94,040
Cash and cash equivalents at end of the period	36,582	38,032
Effect of acquisitions:
Assets acquired, excluding cash	2,372,358	1,428,566
Liabilities assumed	(1,575,380)	(998,738)
Issuance of common stock in connection with acquisition	(216,882)	(380,210)
Cash paid for acquisitions, net of cash acquired	$ 580,096	$ 49,618

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Description of Business Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico. At March 31, 2016, the Company operated 585 behavioral healthcare facilities with over 17,400 beds in 39 states, the United Kingdom and Puerto Rico. Basis of Presentation The business of the Company is conducted through limited liability companies, C-corporations and, for the U.K. facilities, their foreign counterparts. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its’ direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of our financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the fiscal year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 25, 2016. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Certain reclassifications have been made to prior years to conform to the current year presentation.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share	2. Earnings Per Share Basic and diluted earnings per share are calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 260, “ Earnings Per Share The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2016 and 2015 (in thousands, except per share amounts): Three Months Ended 2016 2015 Numerator: Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.: Income from continuing operations $ 25,688 $ 14,592 Income from discontinued operations — 2 Net income attributable to Acadia Healthcare Company, Inc. $ 25,688 $ 14,594 Denominator: Weighted average shares outstanding for basic earnings per share 82,943 62,530 Effect of dilutive instruments 477 364 Shares used in computing diluted earnings per common share 83,420 62,894 Basic earnings per share: Income from continuing operations $ 0.31 $ 0.23 Income from discontinued operations — — Net income $ 0.31 $ 0.23 Diluted earnings per share: Income from continuing operations $ 0.31 $ 0.23 Income from discontinued operations — — Net income $ 0.31 $ 0.23 Approximately 0.8 million and 0.9 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the three months ended March 31, 2016 and 2015, respectively, because their effect would have been anti-dilutive.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Acquisitions	3. Acquisitions Priory On February 16, 2016, the Company completed the acquisition of Priory Group No. 1 Limited (“Priory”) for a total purchase price of approximately $2.2 billion, including total cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of its common stock. Priory is the leading independent provider of behavioral healthcare services in the United Kingdom. The Competition and Markets Authority (“CMA”) in the United Kingdom currently is reviewing our acquisition of Priory. The Company cannot determine when the CMA will complete its review of the acquisition of Priory and, until such review is complete, the Company will not be allowed to integrate Priory’s business. Further, the Company may be required by the CMA to divest part of Priory’s or the Company’s respective businesses. At February 16, 2016, Priory operated 324 facilities with approximately 7,100 beds. 2015 U.S. Acquisitions On December 1, 2015, the Company completed the acquisition of certain facilities from MMO Behavioral Health Systems (“MMO”), including two acute inpatient behavioral health facilities with a total of 80 beds located in Jennings and Covington, Louisiana, for cash consideration of approximately $20.2 million. On November 1, 2015, the Company completed the acquisitions of (i) Discovery House-Group Inc. (“Discovery House”) for cash consideration of approximately $118.5 million and (ii) Duffy’s Napa Valley Rehab (“Duffy’s”) for cash consideration of approximately $29.6 million. Discovery House operates 19 comprehensive treatment centers located in four states. Duffy’s is a substance abuse facility with 61 beds located in Calistoga, California. On August 31, 2015, the Company completed the acquisition of a controlling interest in Southcoast Behavioral (“Southcoast”), an inpatient psychiatric facility located in Fairhaven, Massachusetts. The Company owns 75% of the equity interests in the facility. The value of the 25% noncontrolling interest approximates $9.2 million. The Company considered an income approach and other valuation methodologies to value the noncontrolling interests. The Company consolidates the operations of the facility based on its 75% equity ownership and its management of the entity. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying condensed consolidated balance sheet based on a put right that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control. On July 1, 2015, the Company completed the acquisition of the assets of Belmont Behavioral Health (“Belmont”), an inpatient psychiatric facility with 147 beds located in Philadelphia, Pennsylvania for cash consideration of approximately $39.5 million which consists of $35.0 million base purchase price and an estimated working capital settlement of $4.5 million. On March 1, 2015, the Company acquired the stock of Quality Addiction Management, Inc. (“QAM”) for cash consideration of approximately $54.8 million. QAM operates seven comprehensive treatment centers located in Wisconsin. On February 11, 2015, the Company completed its acquisition of CRC Health Group, Inc. (“CRC”) for total consideration of approximately $1.3 billion. As consideration for the acquisition, the Company issued 5,975,326 shares of its common stock to certain holders of CRC common stock and repaid CRC’s outstanding indebtedness of $904.5 million. CRC is a leading provider of treatment services related to substance abuse and other addiction and behavioral disorders. At the acquisition date, CRC operated 35 inpatient facilities with over 2,400 beds and 81 comprehensive treatment centers located in 30 states. 2015 U.K. Acquisitions On November 1, 2015, the Company completed the acquisition of Cleveland House, an inpatient psychiatric facility with 32 beds located in England, for cash consideration of approximately $10.3 million. On October 1, 2015, the Company completed the acquisition of Meadow View, an inpatient psychiatric facility with 28 beds located in England, for cash consideration of approximately $6.8 million. On September 1, 2015, the Company completed the acquisitions of (i) three facilities from The Danshell Group (“Danshell”) for approximately $59.8 million, (ii) two facilities from Health and Social Care Partnerships (“H&SCP”) for approximately $26.2 million and (iii) Manor Hall for approximately $14.0 million. The inpatient psychiatric facilities acquired from Danshell have an aggregate of 73 beds and are located in England. The inpatient psychiatric facilities acquired from H&SCP have an aggregate of 50 beds and are located in England. Manor Hall has 26 beds and is located in England. On July 1, 2015, the Company completed the acquisition of The Manor Clinic, a substance abuse facility with 15 beds located in England, for cash consideration of approximately $5.9 million. On June 1, 2015, the Company completed the acquisitions of (i) one facility from Choice Lifestyles (“Choice”) for cash consideration of approximately $25.9 million and (ii) 15 facilities from Care UK Limited (“Care UK”) for approximately $88.2 million. The inpatient psychiatric facility acquired from Choice has 42 beds and is located in England. The inpatient psychiatric facilities acquired from Care UK have an aggregate of 299 beds and are located in England. On April 1, 2015, the Company completed the acquisitions of (i) two facilities from Choice for cash consideration of approximately $37.5 million, (ii) Pastoral Care Group (“Pastoral”) for approximately $34.2 million and (iii) Mildmay Oaks f/k/a Vista Independent Hospital (“Mildmay Oaks”) for cash consideration of approximately $14.9 million. The two inpatient psychiatric facilities acquired from Choice have an aggregate of 48 beds and are located in England. Pastoral operates two inpatient psychiatric facilities with an aggregate of 65 beds located in Wales. Mildmay Oaks is an inpatient psychiatric facility with 67 beds located in England. Summary of Acquisitions The Company selectively seeks opportunities to expand and diversify its base of operations by acquiring additional facilities. Approximately $282.7 million of the goodwill associated with domestic acquisitions completed in 2016 and 2015 is deductible for federal income tax purposes. The fair values assigned to certain assets and liabilities assumed by the Company have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. Specifically, the Company is further assessing the valuation of certain real property and intangible assets and certain tax matters as well as certain receivables and assumed liabilities of Priory, MMO, Discovery House, Duffy’s, Cleveland House, Meadow View, Danshell, H&SCP, Manor Hall, The Manor Clinic, Belmont, Choice, Care UK, Pastoral and Mildmay Oaks. The preliminary fair values of assets acquired and liabilities assumed for Priory, at February 16, 2016, were as follows (in thousands): Priory Cash $ 10,253 Accounts receivable 57,831 Prepaid expenses and other current assets 7,920 Property and equipment 1,603,307 Goodwill 652,146 Intangible assets 43,394 Other assets 7,760 Total assets acquired 2,382,611 Accounts payable 24,203 Accrued salaries and benefits 39,588 Other accrued expenses 46,806 Deferred tax liabilities – noncurrent 71,233 Debt 1,348,389 Other liabilities 45,161 Total liabilities assumed 1,575,380 Net assets acquired $ 807,231 The preliminary fair values of assets acquired and liabilities assumed, at the corresponding acquisition dates, during the year ended December 31, 2015 in connection with the 2015 acquisitions were as follows (in thousands): CRC Other Total Cash $ 19,599 $ 5,417 $ 25,016 Accounts receivable 47,035 27,059 74,094 Prepaid expenses and other current assets 26,945 2,738 29,683 Property and equipment 136,163 273,143 409,306 Goodwill 1,043,601 315,010 1,358,611 Intangible assets 37,000 204 37,204 Deferred tax assets-noncurrent 74,383 — 74,383 Other assets 6,478 51 6,529 Total assets acquired 1,391,204 623,622 2,014,826 Accounts payable 4,741 4,564 9,305 Accrued salaries and benefits 14,827 3,321 18,148 Other accrued expenses 38,873 5,291 44,164 Deferred tax liabilities – noncurrent — 13,541 13,541 Debt 904,467 — 904,467 Other liabilities 34,720 10 34,730 Total liabilities assumed 997,628 26,727 1,024,355 Redeemable noncontrolling interests — 9,132 9,132 Net assets acquired $ 393,576 $ 587,763 $ 981,339 Other The qualitative factors comprising the goodwill acquired in the CRC, QAM, Choice, Pastoral, Mildmay Oaks, Care UK, The Manor Clinic, Belmont, Southcoast, Danshell, H&SCP, Manor Hall, Meadow View, Cleveland House, Duffy’s, Discovery House, MMO and Priory acquisitions (collectively the “2015 and 2016 Acquisitions”) include efficiencies derived through synergies expected by the elimination of certain redundant corporate functions and expenses, the ability to leverage call center referrals to a broader provider base, coordination of services provided across the combined network of facilities, achievement of operating efficiencies by benchmarking performance, and applying best practices throughout the combined companies. Transaction-related expenses comprised the following costs for the three months ended March 31, 2016 and 2015 (in thousands): Three Months Ended 2016 2015 Advisory and financing commitment fees $ 14,850 $ 10,337 Legal, accounting and other costs 11,448 3,819 Severance and contract termination costs — 4,260 $ 26,298 $ 18,416 Pro Forma Information The condensed consolidated statements of income for the three months ended March 31, 2016 include revenue of $294.6 million and income from continuing operations before income taxes of $47.6 million related to the 2015 and 2016 Acquisitions. The condensed consolidated statements of income for the three months ended March 31, 2015 include revenue of $68.6 million and income from continuing operations before income taxes of $15.0 million related to acquisitions completed in 2015. The following table provides certain pro forma financial information for the Company as if the 2015 and 2016 Acquisitions occurred as of January 1, 2015 (in thousands): Three Months Ended 2016 2015 Revenue $ 725,667 $ 685,480 Income from continuing operations, before income taxes $ 12,363 $ 14,779

Other Intangible Assets

Other Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangible Assets	4. Other Intangible Assets Other identifiable intangible assets and related accumulated amortization consisted of the following as of March 31, 2016 and December 31, 2015 (in thousands): Gross Carrying Amount Accumulated Amortization March 31, December 31, March 31, December 31, Intangible assets subject to amortization: Contract intangible assets $ 2,100 $ 2,100 $ (1,855 ) $ (1,750 ) Non-compete agreements 1,247 1,247 (1,247 ) (1,247 ) 3,347 3,347 (3,102 ) (2,997 ) Intangible assets not subject to amortization: Licenses and accreditations 11,463 11,479 — — Trade names 80,799 37,800 — — Certificates of need 10,086 9,946 — — 102,348 59,225 — — Total $ 105,695 $ 62,572 $ (3,102 ) $ (2,997 ) In connection with the Priory acquisition, the Company acquired trade name intangible assets with a preliminary fair value of $43.4 million. Amortization expense related to definite-lived intangible assets was $0.1 million for both the three months ended March 31, 2016 and 2015. Estimated amortization expense for the years ending December 31, 2016, 2017, 2018, 2019 and 2020 is $0.4 million, $0, $0, $0 and $0, respectively. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Property and equipment consists of the following as of March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 December 31, 2015 Land $ 838,181 $ 214,138 Building and improvements 2,118,535 1,277,800 Equipment 361,703 141,543 Construction in progress 169,964 195,042 3,488,383 1,828,523 Less accumulated depreciation (150,618 ) (119,470 ) Property and equipment, net $ 3,337,765 $ 1,709,053

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Long-Term Debt	6. Long-Term Debt Long-term debt consisted of the following (in thousands): March 31, 2016 December 31, 2015 Amended and Restated Senior Credit Facility: Senior Secured Term A Loans $ 625,719 $ 500,750 Senior Secured Term B Loans 1,446,362 495,000 Senior Secured Revolving Line of Credit 50,000 158,000 6.125% Senior Notes due 2021 150,000 150,000 5.125% Senior Notes due 2022 300,000 300,000 5.625% Senior Notes due 2023 650,000 650,000 6.500% Senior Notes due 2024 390,000 — 9.0% and 9.5% Revenue Bonds 22,410 22,410 Less: unamortized debt issuance costs, discount and premium (67,699 ) (35,416 ) 3,566,792 2,240,744 Less: current portion (69,223 ) (45,360 ) Long-term debt $ 3,497,569 $ 2,195,384 Amended and Restated Senior Credit Facility The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”). The Company has amended the Amended and Restated Credit Agreement from time to time as described in the Company’s prior filings with the Securities and Exchange Commission. On February 6, 2015, the Company entered into a Seventh Amendment (the “Seventh Amendment”) to the Amended and Restated Credit Agreement. The Seventh Amendment added Citibank, N.A. as an “L/C Issuer” under the Amended and Restated Credit Agreement in order to permit the rollover of CRC’s existing letters of credit into the Amended and Restated Credit Agreement and increased both the Company’s Letter of Credit Sublimit and Swing Line Sublimit to $20.0 million. On February 11, 2015, the Company entered into a First Incremental Facility Amendment (the “First Incremental Amendment”) to the Amended and Restated Credit Agreement. The First Incremental Amendment activated a new $500.0 million incremental Term Loan B facility (the “Existing TLB Facility”) that was added to the Amended and Restated Senior Credit Facility, subject to limited conditionality provisions. Borrowings under the Existing TLB Facility were used to fund a portion of the purchase price for the acquisition of CRC. On April 22, 2015, the Company entered into an Eighth Amendment (the “Eighth Amendment”) to the Amended and Restated Credit Agreement. The Eighth Amendment changed the definition of “Change of Control” in part to remove a provision whose purpose was, when calculating whether a majority of incumbent directors have approved new directors, that any incumbent director that became a director as a result of a threatened or actual proxy contest was not counted in such calculation. On January 25, 2016, the Company entered into the Ninth Amendment (the “Ninth Amendment”) to the Amended and Restated Credit Agreement. The Ninth Amendment modifies certain definitions and provides increased flexibility to the Company in terms of its financial covenants. The Company’s baskets for permitted investments were also increased to provide increased flexibility for it to invest in non-wholly owned subsidiaries, joint ventures and foreign subsidiaries. The Company may now invest in non-wholly owned subsidiaries and joint ventures up to 10.0% of the Company and its subsidiaries’ total assets in any four consecutive fiscal quarter period, and up to 12.5% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The Company may also invest in foreign subsidiaries that are not loan parties up to 10% of the Company and its subsidiaries’ total assets in any consecutive four fiscal quarter period, and up to 15% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The foregoing permitted investments are subject to an aggregate cap of 25% of the Company and its subsidiaries’ total assets in any fiscal year. On February 16, 2016, the Company entered into a Second Incremental Facility Amendment (the “Second Incremental Amendment”) to the Amended and Restated Credit Agreement. The Second Incremental Amendment activated a new $955.0 million incremental Term Loan B facility (the “New TLB Facility”) and added $135.0 million to the Term Loan A facility (the “TLA Facility”) to the Amended and Restated Senior Credit Facility, subject to limited conditionality provisions. Borrowings under the New TLB Facility were used to fund a portion of the purchase price for the acquisition of Priory and the fees and expenses for such acquisition and the related financing transactions. Borrowings under the TLA Facility were used to pay down the majority of our $300.0 million revolving credit facility. The Company had $241.5 million of availability under the revolving line of credit as of March 31, 2016. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our TLA Facility of $10.0 million for March 31, 2016, $12.6 million for June 30, 2016 to December 31, 2016, $16.8 million for March 31, 2017 to December 31, 2017, and $20.9 million for March 31, 2018 to December 31, 2018, with the remaining principal balance of the TLA Facility due on the maturity date of February 13, 2019. The Company is required to repay the Existing TLB Facility in equal quarterly installments of $1.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Existing TLB Facility due on February 11, 2022. The Company is required to repay the New TLB Facility in equal quarterly installments of approximately $2.4 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TLB Facility due on February 16, 2023. Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $40.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 3.25% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 2.25% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at March 31, 2016. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As of March 31, 2016, the Pro Rata Facilities bore interest at a rate of LIBOR plus 3.25%. In addition, the Company is required to pay a commitment fee on undrawn amounts under the revolving line of credit. The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. As of March 31, 2016, the Company was in compliance with such covenants. Senior Notes 6.125% Senior Notes due 2021 On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. 5.125% Senior Notes due 2022 On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year. 5.625% Senior Notes due 2023 On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year. On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes form a single class of debt securities with the existing 5.625% Senior Notes. Giving effect to this issuance, the Company has outstanding an aggregate of $650.0 million of 5.625% Senior Notes. 6.500% Senior Notes due 2024 On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016. The indentures governing the 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets. The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several. The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures. 9.0% and 9.5% Revenue Bonds On November 11, 2012, in connection with the acquisition of Park Royal, the Company assumed debt of $23.0 million. The fair market value of the debt assumed was $25.6 million and resulted in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (“9.0% and 9.5% Revenue Bonds”), respectively. The 9.0% bonds in the amount of $7.5 million have a maturity date of December 1, 2030 and require yearly principal payments beginning in 2013. The 9.5% bonds in the amount of $15.5 million have a maturity date of December 1, 2040 and require yearly principal payments beginning in 2031. The principal payments establish a bond sinking fund to be held with the trustee and shall be sufficient to redeem the principal amounts of the 9.0% and 9.5% Revenue Bonds on their respective maturity dates. As of March 31, 2016 and December 31, 2015, $2.3 million was recorded within other assets on the balance sheet related to the debt service reserve fund requirements. The yearly principal payments, which establish a bond sinking fund, will increase the debt service reserve fund requirements. The bond premium amount of $2.6 million is amortized as a reduction of interest expense over the life of the revenue bonds using the effective interest method.

Equity

Equity	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Equity	7. Equity Common Stock On March 3, 2016, the Company held a Special Meeting of Stockholders, where the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 90,000,000 to 180,000,000 (the “Amendment”). On March 3, 2016, the Company filed the Amendment with the Secretary of State of the State of Delaware. Equity Offerings On February 11, 2015, the Company completed its acquisition of CRC for total consideration of approximately $1.3 billion. As consideration for the acquisition, the Company issued 5,975,326 shares of its common stock to certain holders of CRC common stock and repaid CRC’s outstanding indebtedness. On May 11, 2015, the Company completed the offering of 5,175,000 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $66.50 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $12.0 million and additional offering-related costs of $0.8 million, were $331.3 million. The Company used the net offering proceeds to repay outstanding indebtedness and fund acquisitions. On January 12, 2016, the Company completed the offering of 11,500,000 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $61.00 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $15.8 million and additional offering-related costs of $0.7 million, were $685.0 million. The Company used the net offering proceeds to fund a portion of the purchase price for the acquisition of Priory. On February 16, 2016, the Company completed its acquisition of Priory for a total purchase price of approximately $2.2 billion, including total cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of common stock.

Equity-Based Compensation

Equity-Based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity-Based Compensation	8. Equity-Based Compensation Equity Incentive Plans The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). As of March 31, 2016, a maximum of 4,700,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 1,336,703 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the most recent closing price of the Company’s common stock on the date of grant. The Company recognized $7.0 million and $3.9 million in equity-based compensation expense for the three months ended March 31, 2016 and 2015, respectively. As of March 31, 2016, there was $65.7 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.5 years. The Company recognized a deferred income tax benefit of $2.8 million and $1.6 million for the three months ended March 31, 2016 and 2015, respectively, related to equity-based compensation expense. The actual tax benefit realized from stock options exercised during the three months ended March 31, 2015 was $4.3 million. No tax benefit was realized from stock options during the three months ended March 31, 2016. Stock option activity during 2015 and 2016 was as follows (aggregate intrinsic value in thousands): Number Options Weighted Weighted Aggregate Options outstanding at January 1, 2015 737,422 $ 32.19 8.09 $ 14,512 Options granted 204,700 63.07 9.21 1,724 Options exercised (214,079 ) 42.75 N/A 9,890 Options cancelled (33,300 ) 46.53 N/A N/A Options outstanding at December 31, 2015 694,743 42.87 7.70 20,717 Options granted 294,350 59.72 9.86 — Options exercised (7,075 ) 32.00 N/A 278 Options cancelled (16,775 ) 57.99 N/A N/A Options outstanding at March 31, 2016 965,243 $ 47.86 8.20 $ 11,884 Options exercisable at December 31, 2015 106,330 $ 36.41 5.83 $ 4,968 Options exercisable at March 31, 2016 323,979 $ 40.58 6.76 $ 8,527 Restricted stock activity during 2015 and 2016 was as follows: Number of Weighted Grant-Date Unvested at January 1, 2015 722,028 $ 39.77 Granted 503,052 62.67 Cancelled (44,900 ) 49.55 Vested (235,618 ) 34.93 Unvested at December 31, 2015 944,562 $ 52.74 Granted 188,587 59.72 Cancelled (32,050 ) 59,79 Vested (213,787 ) 47.18 Unvested at March 31, 2016 887,312 $ 55.30 Restricted stock unit activity during 2015 and 2016 was as follows: Number of Weighted Grant-Date Unvested at January 1, 2015 125,113 $ 38.73 Granted 217,994 61.77 Cancelled — — Vested (125,023 ) 32.38 Unvested at December 31, 2015 218,084 $ 56.97 Granted 230,750 56.95 Cancelled — — Vested (175,235 ) 52.71 Unvested at March 31, 2016 273,599 $ 59.68 The grant-date fair value of the Company’s stock options is estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the three months ended March 31, 2016 and year ended December 31, 2015: March 31, 2016 December 31, 2015 Weighted average grant-date fair value of options $ 19.57 $ 21.78 Risk-free interest rate 1.4 % 1.5 % Expected volatility 33 % 35 % Expected life (in years) 5.5 5.5 The Company’s estimate of expected volatility for stock options is based upon the volatility of guideline companies given the lack of sufficient historical trading experience of the Company’s common stock. The risk-free interest rate is the approximate yield on United States Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The provision for income taxes for continuing operations for the three months ended March 31, 2016 and 2015 reflects effective tax rates of 21.9% and 31.2%, respectively. The decrease in the tax rate for the three months ended March 31, 2016 was primarily attributable to the acquisition of Priory, which is located in a lower taxing jurisdiction and for which earnings are permanently reinvested.

Derivatives

Derivatives	3 Months Ended
	Mar. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	10. Derivatives The Company entered into foreign currency forward contracts during both the three months ended March 31, 2016 and 2015 in connection with acquisitions in the United Kingdom. The foreign currency forward contracts limited the economic risk of changes in the foreign exchange rate between US Dollars (“USD”) and British Pounds (“GBP”) associated with the payment of the purchase price in GBP. These foreign currency forward contracts did not meet the hedge accounting criteria under Accounting Standards Codification 815, Derivatives and Hedging

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	11. Fair Value Measurements The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments. The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 9.0% and 9.5% Revenue Bonds and contingent consideration liabilities as of March 31, 2016 and December 31, 2015 were as follows (in thousands): Carrying Amount Fair Value March 31, December 31, March 31, December 31, Amended and Restated Senior Credit Facility $ 2,079,958 $ 1,135,861 $ 2,079,958 $ 1,135,861 6.125% Senior Notes due 2021 $ 147,202 $ 147,082 $ 152,354 $ 149,288 5.125% Senior Notes due 2022 $ 294,919 $ 294,749 $ 297,868 $ 275,590 5.625% Senior Notes due 2023 $ 639,672 $ 639,431 $ 653,767 $ 604,262 6.500% Senior Notes due 2024 $ 381,528 $ — $ 396,789 $ — 9.0% and 9.5% Revenue Bonds $ 23,514 $ 23,621 $ 23,514 $ 23,621 Contingent consideration liabilities $ 667 $ 667 $ 667 $ 667 The Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes and 9.0% and 9.5% Revenue Bonds were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates. The fair value of the contingent consideration liabilities were categorized as Level 3 in the GAAP fair value hierarchy. The contingent consideration liabilities were valued using a probability-weighted discounted cash flow method. This analysis reflected the contractual terms of the purchase agreements and utilized assumptions with regard to future earnings, probabilities of achieving such future earnings and a discount rate.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies The Company is, from time to time, subject to various claims and legal actions that arise in the ordinary course of the Company’s business, including claims for damages for personal injuries, medical malpractice, breach of contract, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In the opinion of management, the Company is not currently a party to any proceeding that would individually or in the aggregate have a material adverse effect on the Company’s business, financial condition or results of operations.

Current Assets

Current Assets	3 Months Ended
	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Current Assets	13. Current Assets Other current assets consisted of the following (in thousands): March 31, December 31, Prepaid expenses $ 29,397 $ 21,817 Other receivables 22,877 17,518 Insurance receivable – current portion 5,290 5,290 Workers’ compensation deposits – current portion 7,500 7,500 Income taxes receivable 6,676 6,540 Inventory 4,779 4,681 Other 3,284 3,549 Other current assets $ 79,803 $ 66,895

Other Accrued Liabilities

Other Accrued Liabilities	3 Months Ended
	Mar. 31, 2016
Other Liabilities Disclosure [Abstract]
Other Accrued Liabilities	14. Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands): March 31, December 31, Unearned income $ 24,608 $ 446 Accrued interest 15,868 26,132 Insurance liability – current portion 10,490 10,490 Other current liabilities 8,797 7,499 Income taxes payable 4,039 7,367 Accrued property taxes 2,829 2,951 Other 42,032 17,921 Other accrued liabilities $ 108,663 $ 72,806

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segment Information	15. Segment Information The Company operates in one line of business, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its facilities in the United States (the “U.S. Facilities”) and its facilities in the United Kingdom (the “U.K. Facilities”) separately to assess performance and make decisions, the Company’s operating segments include its U.S. Facilities and U.K. Facilities. At March 31, 2016, the U.S. Facilities included 205 behavioral healthcare facilities with approximately 8,000 beds in 39 states and Puerto Rico, and the U.K. Facilities included 380 behavioral healthcare facilities with approximately 9,400 beds in the United Kingdom. The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands): Three Months Ended March 31, 2016 2015 Revenue: U.S. Facilities $ 408,264 $ 290,507 U.K. Facilities 206,975 73,315 Corporate and Other 1,574 1,961 $ 616,813 $ 365,783 Segment EBITDA (1): U.S. Facilities $ 106,840 $ 76,364 U.K. Facilities 44,931 18,811 Corporate and Other (20,759 ) (16,463 ) $ 131,012 $ 78,712 Three Months Ended March 31, 2016 2015 Segment EBITDA (1) $ 131,012 $ 78,712 Plus (less): Equity-based compensation expense (6,956 ) (3,894 ) Gain on foreign currency derivatives 410 53 Transaction-related expenses (26,298 ) (18,416 ) Interest expense, net (37,714 ) (22,146 ) Depreciation and amortization (27,975 ) (13,104 ) Income from continuing operations before income taxes $ 32,479 $ 21,205 U.S. Facilities U.K. Facilities Corporate Consolidated Goodwill: Balance at January 1, 2016 $ 1,941,873 $ 186,342 $ — $ 2,128,215 Increase from 2016 acquisitions — 652,146 — 652,146 Foreign currency translation loss — (11,406 ) — (11,406 ) Other 2,371 39 — 2,410 Balance at March 31, 2016 $ 1,944,244 $ 827,121 $ — $ 2,771,365 March 31, 2016 December 31, 2015 Assets (2): U.S. Facilities $ 3,138,727 $ 3,061,519 U.K. Facilities 3,390,950 1,045,922 Corporate and Other 166,682 171,767 $ 6,696,359 $ 4,279,208 (1) Segment EBITDA is defined as income from continuing operations before provision for income taxes, equity-based compensation expense, gain on foreign currency derivatives, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. (2) Assets include property and equipment for the U.S. Facilities of $885.2 million, U.K. Facilities of $2.4 billion and corporate and other of $42.8 million at March 31, 2016. Assets include property and equipment for the U.S. Facilities of $832.2 million, U.K. Facilities of $824.4 million and corporate and other of $52.4 million at December 31, 2015.

Recently Issued Accounting Stan

Recently Issued Accounting Standards	3 Months Ended
	Mar. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Standards	16. Recently Issued Accounting Standards In March 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Improvements to Employee Share-Based Payment Accounting” In March 2016, FASB issued ASU 2016-02, “Leases”

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events On April 1, 2016, the Company completed the acquisition of Serenity Knolls, an inpatient psychiatric facility with 30 beds located in Forest Knolls, California, for cash consideration of approximately $10.0 million.

Financial Information for the C

Financial Information for the Company and Its Subsidiaries	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Financial Information for the Company and Its Subsidiaries	18. Financial Information for the Company and Its Subsidiaries The Company conducts substantially all of its business through its subsidiaries. The 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Presented below is condensed consolidating financial information for the Company and its subsidiaries as of March 31, 2016 and December 31, 2015, and for the three months ended March 31, 2016 and 2015. The information segregates the parent company (Acadia Healthcare Company, Inc.), the combined wholly-owned subsidiary guarantors, the combined non-guarantor subsidiaries and eliminations. Acadia Healthcare Company, Inc. Condensed Consolidating Balance Sheets March 31, 2016 (In thousands) Parent Combined Combined Consolidating Total Current assets: Cash and cash equivalents $ — $ 17,069 $ 19,513 $ — $ 36,582 Accounts receivable, net — 200,870 76,010 — 276,880 Other current assets — 65,826 20,879 (6,902 ) 79,803 Total current assets — 283,765 116,402 (6,902 ) 393,265 Property and equipment, net — 848,951 2,488,814 — 3,337,765 Goodwill — 1,837,710 933,655 — 2,771,365 Intangible assets, net — 57,059 45,534 — 102,593 Deferred tax assets – noncurrent 3,946 32,981 4,826 — 41,753 Investment in subsidiaries 5,266,912 — — (5,266,912 ) — Other assets 849,968 36,606 10,029 (846,985 ) 49,618 Total assets $ 6,120,826 $ 3,097,072 $ 3,599,260 $ (6,120,799 ) $ 6,696,359 Current liabilities: Current portion of long-term debt $ 68,988 $ — $ 235 $ — $ 69,223 Accounts payable — 75,861 42,349 — 118,210 Accrued salaries and benefits — 72,272 40,442 — 112,714 Other accrued liabilities 14,678 — 100,887 (6,902 ) 108,663 Total current liabilities 83,666 148,133 183,913 (6,902 ) 408,810 Long-term debt 3,474,290 — 870,264 (846,985 ) 3,497,569 Deferred tax liabilities – noncurrent — — 94,882 — 94,882 Other liabilities — 78,979 45,513 — 124,492 Total liabilities 3,557,956 227,112 1,194,572 (853,887 ) 4,125,753 Redeemable noncontrolling interests — — 7,736 — 7,736 Total equity 2,562,870 2,869,960 2,396,952 (5,266,912 ) 2,562,870 Total liabilities and equity $ 6,120,826 $ 3,097,072 $ 3,599,260 $ (6,120,799 ) $ 6,696,359 Acadia Healthcare Company, Inc. Condensed Consolidating Balance Sheets December 31, 2015 (In thousands) Parent Combined Combined Consolidating Total Current assets: Cash and cash equivalents $ — $ 1,987 $ 9,228 $ — $ 11,215 Accounts receivable, net — 187,546 29,080 — 216,626 Other current assets — 57,968 8,927 — 66,895 Total current assets — 247,501 47,235 — 294,736 Property and equipment, net — 805,439 903,614 — 1,709,053 Goodwill — 1,835,339 292,876 — 2,128,215 Intangible assets, net — 57,024 2,551 — 59,575 Deferred tax assets – noncurrent 3,946 40,587 4,581 — 49,114 Investment in subsidiaries 3,495,067 — — (3,495,067 ) — Other assets 427,270 32,947 2,322 (424,024 ) 38,515 Total assets $ 3,926,283 $ 3,018,837 $ 1,253,179 $ (3,919,091 ) $ 4,279,208 Current liabilities: Current portion of long-term debt $ 45,125 $ — $ 235 $ — $ 45,360 Accounts payable — 75,015 16,326 — 91,341 Accrued salaries and benefits — 66,249 14,447 — 80,696 Other accrued liabilities 26,132 10,886 35,788 — 72,806 Total current liabilities 71,257 152,150 66,796 — 290,203 Long-term debt 2,171,998 — 447,410 (424,024 ) 2,195,384 Deferred tax liabilities – noncurrent — — 23,936 — 23,936 Other liabilities — 75,159 3,443 — 78,602 Total liabilities 2,243,255 227,309 541,585 (424,024 ) 2,588,125 Redeemable noncontrolling interests — — 8,055 — 8,055 Total equity 1,683,028 2,791,528 703,539 (3,495,067 ) 1,683,028 Total liabilities and equity $ 3,926,283 $ 3,018,837 $ 1,253,179 $ (3,919,091 ) $ 4,279,208 Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Comprehensive Income (Loss) Three Months Ended March 31, 2016 (In thousands) Parent Combined Combined Consolidating Total Revenue before provision for doubtful accounts $ — $ 402,934 $ 224,249 $ — $ 627,183 Provision for doubtful accounts — (9,342 ) (1,028 ) — (10,370 ) Revenue — 393,592 223,221 — 616,813 Salaries, wages and benefits 6,956 211,033 123,039 — 341,028 Professional fees — 22,677 17,314 — 39,991 Supplies — 18,462 8,223 — 26,685 Rents and leases — 8,577 6,229 — 14,806 Other operating expenses — 48,849 21,398 — 70,247 Depreciation and amortization — 12,751 15,224 — 27,975 Interest expense, net 13,433 16,093 8,188 — 37,714 Gain on foreign currency derivatives (410 ) — — — (410 ) Transaction-related expenses — 21,435 4,863 — 26,298 Total expenses 19,979 359,877 204,478 — 584,334 (Loss) income from continuing operations before income taxes (19,979 ) 33,715 18,743 — 32,479 Equity in earnings of subsidiaries 40,869 — — (40,869 ) — (Benefit from) provision for income taxes (4,479 ) 7,407 4,182 — 7,110 Income (loss) from continuing operations 25,369 26,308 14,561 (40,869 ) 25,369 Income from discontinued operations, net of income taxes — — — — — Net income (loss) 25,369 26,308 14,561 (40,869 ) 25,369 Net loss attributable to noncontrolling interests — — 319 — 319 Net income (loss) attributable to Acadia Healthcare $ 25,369 $ 26,308 $ 14,880 $ (40,869 ) $ 25,688 Other comprehensive loss: Foreign currency translation loss — — (48,415 ) — (48,415 ) Other comprehensive loss — — (48,415 ) — (48,415 ) Comprehensive income (loss) $ 25,369 $ 26,308 $ (33,535 ) $ (40,869 ) $ (22,727 ) Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Comprehensive Income (Loss) Three Months Ended March 31, 2015 (In thousands) Parent Combined Combined Consolidating Total Revenue before provision for doubtful accounts $ — $ 287,765 $ 86,393 $ — $ 374,158 Provision for doubtful accounts — (7,419 ) (956 ) — (8,375 ) Revenue — 280,346 85,437 — 365,783 Salaries, wages and benefits 3,894 155,699 46,278 — 205,871 Professional fees — 16,485 5,942 — 22,427 Supplies — 13,009 3,245 — 16,254 Rents and leases — 5,117 769 — 5,886 Other operating expenses — 25,115 15,412 — 40,527 Depreciation and amortization — 8,711 4,393 — 13,104 Interest expense, net 12,948 5,721 3,477 — 22,146 Gain on foreign currency derivatives (53 ) — — — (53 ) Transaction-related expenses — 18,416 — — 18,416 Total expenses 16,789 248,273 79,516 — 344,578 (Loss) income from continuing operations before income taxes (16,789 ) 32,073 5,921 — 21,205 Equity in earnings of subsidiaries 25,987 — — (25,987 ) — (Benefit from) provision for income taxes (5,396 ) 10,497 1,512 — 6,613 Income (loss) from continuing operations 14,594 21,576 4,409 (25,987 ) 14,592 Income from discontinued operations, net of income taxes — 2 — — 2 Net income (loss) $ 14,594 $ 21,578 $ 4,409 $ (25,987 ) $ 14,594 Other comprehensive loss: Foreign currency translation loss — — (29,389 ) — (29,389 ) Other comprehensive loss — — (29,389 ) — (29,389 ) Comprehensive income (loss) $ 14,594 $ 21,578 $ (24,980 ) $ (25,987 ) $ (14,795 ) Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Cash Flows Three Months Ended March 31, 2016 (In thousands) Parent Combined Combined Consolidating Total Operating activities: Net income (loss) $ 25,369 $ 26,308 $ 14,561 $ (40,869 ) $ 25,369 Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities: Equity in earnings of subsidiaries (40,869 ) — — 40,869 — Depreciation and amortization — 12,751 15,224 — 27,975 Amortization of debt issuance costs 2,254 — (107 ) — 2,147 Equity-based compensation expense 6,956 — — — 6,956 Deferred income tax (benefit) expense — 8,846 239 — 9,085 Gain on foreign currency derivatives (410 ) — — — (410 ) Other — 896 (14 ) — 882 Change in operating assets and liabilities, net of effect of acquisitions: Accounts receivable, net — (13,560 ) 9,811 — (3,749 ) Other current assets — (3,596 ) (4,479 ) — (8,075 ) Other assets — (1,992 ) (410 ) — (2,402 ) Accounts payable and other accrued liabilities — 7,564 (66 ) — 7,498 Accrued salaries and benefits — 6,388 (12,735 ) — (6,347 ) Other liabilities — 4,416 (4,062 ) — 354 Net cash (used in) provided by continuing operating activities (6,700 ) 48,021 17,962 — 59,283 Net cash used in discontinued operating activities — (619 ) — — (619 ) Net cash (used in) provided by operating activities (6,700 ) 47,402 17,962 — 58,664 Investing activities: Cash paid for acquisitions, net of cash acquired — — (580,096 ) — (580,096 ) Cash paid for capital expenditures — (64,272 ) (25,817 ) — (90,089 ) Cash paid for real estate acquisitions — (2,998 ) (11,801 ) — (14,799 ) Settlement of foreign currency derivatives — 745 — — 745 Other — (1,208 ) — — (1,208 ) Net cash used in investing activities — (67,733 ) (617,714 ) — (685,447 ) Financing activities: Borrowings on long-term debt 1,480,000 — — — 1,480,000 Borrowings on revolving credit facility 58,000 — — — 58,000 Principal payments on revolving credit facility (166,000 ) — — — (166,000 ) Principal payments on long-term debt (13,669 ) — — — (13,669 ) Repayment of assumed debt (1,348,389 ) — — — (1,348,389 ) Payment of debt issuance costs (34,167 ) — — — (34,167 ) Issuance of common stock 685,097 — — — 685,097 Common stock withheld for minimum statutory taxes, net (6,679 ) — — — (6,679 ) Excess tax benefit from equity awards — — — — — Other — (224 ) — — (224 ) Cash (used in) provided by intercompany activity (647,493 ) 35,637 611,856 — — Net cash provided by financing activities 6,700 35,413 611,856 — 653,969 Effect of exchange rate changes on cash — — (1,819 ) — (1,819 ) Net increase in cash and cash equivalents — 15,082 10,285 — 25,367 Cash and cash equivalents at beginning of the period — 1,987 9,228 — 11,215 Cash and cash equivalents at end of the period $ — $ 17,069 $ 19,513 $ — $ 36,582 Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Cash Flows Three Months Ended March 31, 2015 (In thousands) Parent Combined Combined Consolidating Total Operating activities: Net income (loss) $ 14,594 $ 21,578 $ 4,409 $ (25,987 ) $ 14,594 Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities: Equity in earnings of subsidiaries (25,987 ) — — 25,987 — Depreciation and amortization — 8,711 4,393 — 13,104 Amortization of debt issuance costs 1,578 — (110 ) — 1,468 Equity-based compensation expense 3,894 — — — 3,894 Deferred income tax (benefit) expense 646 18,354 224 — 19,224 Loss from discontinued operations, net of taxes — (2 ) — — (2 ) Gain on foreign currency derivatives (53 ) — — — (53 ) Other — 364 14 — 378 Change in operating assets and liabilities, net of effect of acquisitions: — Accounts receivable, net — (8,265 ) 1,308 — (6,957 ) Other current assets — (24,182 ) 424 — (23,758 ) Other assets — (638 ) 2 — (636 ) Accounts payable and other accrued liabilities — 6,645 (5,371 ) — 1,274 Accrued salaries and benefits — (4,440 ) (582 ) — (5,022 ) Other liabilities — 762 (182 ) — 580 Net cash (used in) provided by continuing operating activities (5,328 ) 18,887 4,529 — 18,088 Net cash provided by discontinued operating activities — 134 — — 134 Net cash (used in) provided by operating activities (5,328 ) 19,021 4,529 — 18,222 Investing activities: Cash paid for acquisitions, net of cash acquired — (48,317 ) (1,301 ) — (49,618 ) Cash paid for capital expenditures — (41,426 ) (11,453 ) — (52,879 ) Cash paid for real estate acquisitions — (1,722 ) — — (1,722 ) Other — (383 ) — — (383 ) Net cash used in investing activities — (91,848 ) (12,754 ) — (104,602 ) Financing activities: Borrowings on long-term debt 875,000 — — — 875,000 Borrowings on revolving credit facility 93,000 — — — 93,000 Principal payments on long-term debt (7,938 ) — — — (7,938 ) Repayment of assumed debt (904,467 ) — — — (904,467 ) Payment of debt issuance costs (22,191 ) — — — (22,191 ) Common stock withheld for minimum statutory taxes, net (5,110 ) — — — (5,110 ) Excess tax benefit from equity awards 4,310 — — — 4,310 Cash (used in) provided by intercompany activity (27,276 ) 10,964 16,312 — — Net cash provided by financing activities 5,328 10,964 16,312 — 32,604 Effect of exchange rate changes on cash — — (2,232 ) — (2,232 ) Net (decrease) increase in cash and cash equivalents — (61,863 ) 5,855 — (56,008 ) Cash and cash equivalents at beginning of the period — 76,685 17,355 — 94,040 Cash and cash equivalents at end of the period $ — $ 14,822 $ 23,210 $ — $ 38,032

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2016 and 2015 (in thousands, except per share amounts): Three Months Ended 2016 2015 Numerator: Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.: Income from continuing operations $ 25,688 $ 14,592 Income from discontinued operations — 2 Net income attributable to Acadia Healthcare Company, Inc. $ 25,688 $ 14,594 Denominator: Weighted average shares outstanding for basic earnings per share 82,943 62,530 Effect of dilutive instruments 477 364 Shares used in computing diluted earnings per common share 83,420 62,894 Basic earnings per share: Income from continuing operations $ 0.31 $ 0.23 Income from discontinued operations — — Net income $ 0.31 $ 0.23 Diluted earnings per share: Income from continuing operations $ 0.31 $ 0.23 Income from discontinued operations — — Net income $ 0.31 $ 0.23

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2016
Transaction Related Expenses as Incurred	Transaction-related expenses comprised the following costs for the three months ended March 31, 2016 and 2015 (in thousands): Three Months Ended 2016 2015 Advisory and financing commitment fees $ 14,850 $ 10,337 Legal, accounting and other costs 11,448 3,819 Severance and contract termination costs — 4,260 $ 26,298 $ 18,416
Pro Forma Financial Information for Acquisitions Occurred	The following table provides certain pro forma financial information for the Company as if the 2015 and 2016 Acquisitions occurred as of January 1, 2015 (in thousands): Three Months Ended 2016 2015 Revenue $ 725,667 $ 685,480 Income from continuing operations, before income taxes $ 12,363 $ 14,779
Priory [Member]
Preliminary Fair Values of Assets Acquired and Liabilities Assumed at Corresponding Acquisition Date	The preliminary fair values of assets acquired and liabilities assumed for Priory, at February 16, 2016, were as follows (in thousands): Cash $ 10,253 Accounts receivable 57,831 Prepaid expenses and other current assets 7,920 Property and equipment 1,603,307 Goodwill 652,146 Intangible assets 43,394 Other assets 7,760 Total assets acquired 2,382,611 Accounts payable 24,203 Accrued salaries and benefits 39,588 Other accrued expenses 46,806 Deferred tax liabilities – noncurrent 71,233 Debt 1,348,389 Other liabilities 45,161 Total liabilities assumed 1,575,380 Net assets acquired $ 807,231
CRC Health Group Inc and Other Acquisitions [Member]
Preliminary Fair Values of Assets Acquired and Liabilities Assumed at Corresponding Acquisition Date	The preliminary fair values of assets acquired and liabilities assumed, at the corresponding acquisition dates, during the year ended December 31, 2015 in connection with the 2015 acquisitions were as follows (in thousands): CRC Other Total Cash $ 19,599 $ 5,417 $ 25,016 Accounts receivable 47,035 27,059 74,094 Prepaid expenses and other current assets 26,945 2,738 29,683 Property and equipment 136,163 273,143 409,306 Goodwill 1,043,601 315,010 1,358,611 Intangible assets 37,000 204 37,204 Deferred tax assets-noncurrent 74,383 — 74,383 Other assets 6,478 51 6,529 Total assets acquired 1,391,204 623,622 2,014,826 Accounts payable 4,741 4,564 9,305 Accrued salaries and benefits 14,827 3,321 18,148 Other accrued expenses 38,873 5,291 44,164 Deferred tax liabilities – noncurrent — 13,541 13,541 Debt 904,467 — 904,467 Other liabilities 34,720 10 34,730 Total liabilities assumed 997,628 26,727 1,024,355 Redeemable noncontrolling interests — 9,132 9,132 Net assets acquired $ 393,576 $ 587,763 $ 981,339

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Other Identifiable Intangible Assets and Related Accumulated Amortization	Other identifiable intangible assets and related accumulated amortization consisted of the following as of March 31, 2016 and December 31, 2015 (in thousands): Gross Carrying Amount Accumulated Amortization March 31, December 31, March 31, December 31, Intangible assets subject to amortization: Contract intangible assets $ 2,100 $ 2,100 $ (1,855 ) $ (1,750 ) Non-compete agreements 1,247 1,247 (1,247 ) (1,247 ) 3,347 3,347 (3,102 ) (2,997 ) Intangible assets not subject to amortization: Licenses and accreditations 11,463 11,479 — — Trade names 80,799 37,800 — — Certificates of need 10,086 9,946 — — 102,348 59,225 — — Total $ 105,695 $ 62,572 $ (3,102 ) $ (2,997 )

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consists of the following as of March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 December 31, 2015 Land $ 838,181 $ 214,138 Building and improvements 2,118,535 1,277,800 Equipment 361,703 141,543 Construction in progress 169,964 195,042 3,488,383 1,828,523 Less accumulated depreciation (150,618 ) (119,470 ) Property and equipment, net $ 3,337,765 $ 1,709,053

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Components of Long-Term Debt	Long-term debt consisted of the following (in thousands): March 31, 2016 December 31, 2015 Amended and Restated Senior Credit Facility: Senior Secured Term A Loans $ 625,719 $ 500,750 Senior Secured Term B Loans 1,446,362 495,000 Senior Secured Revolving Line of Credit 50,000 158,000 6.125% Senior Notes due 2021 150,000 150,000 5.125% Senior Notes due 2022 300,000 300,000 5.625% Senior Notes due 2023 650,000 650,000 6.500% Senior Notes due 2024 390,000 — 9.0% and 9.5% Revenue Bonds 22,410 22,410 Less: unamortized debt issuance costs, discount and premium (67,699 ) (35,416 ) 3,566,792 2,240,744 Less: current portion (69,223 ) (45,360 ) Long-term debt $ 3,497,569 $ 2,195,384

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Activity	Stock option activity during 2015 and 2016 was as follows (aggregate intrinsic value in thousands): Number Options Weighted Weighted Aggregate Options outstanding at January 1, 2015 737,422 $ 32.19 8.09 $ 14,512 Options granted 204,700 63.07 9.21 1,724 Options exercised (214,079 ) 42.75 N/A 9,890 Options cancelled (33,300 ) 46.53 N/A N/A Options outstanding at December 31, 2015 694,743 42.87 7.70 20,717 Options granted 294,350 59.72 9.86 — Options exercised (7,075 ) 32.00 N/A 278 Options cancelled (16,775 ) 57.99 N/A N/A Options outstanding at March 31, 2016 965,243 $ 47.86 8.20 $ 11,884 Options exercisable at December 31, 2015 106,330 $ 36.41 5.83 $ 4,968 Options exercisable at March 31, 2016 323,979 $ 40.58 6.76 $ 8,527
Restricted Stock Activity	Restricted stock activity during 2015 and 2016 was as follows: Number of Weighted Grant-Date Unvested at January 1, 2015 722,028 $ 39.77 Granted 503,052 62.67 Cancelled (44,900 ) 49.55 Vested (235,618 ) 34.93 Unvested at December 31, 2015 944,562 $ 52.74 Granted 188,587 59.72 Cancelled (32,050 ) 59,79 Vested (213,787 ) 47.18 Unvested at March 31, 2016 887,312 $ 55.30
Restricted Stock Unit Activity	Restricted stock unit activity during 2015 and 2016 was as follows: Number of Weighted Grant-Date Unvested at January 1, 2015 125,113 $ 38.73 Granted 217,994 61.77 Cancelled — — Vested (125,023 ) 32.38 Unvested at December 31, 2015 218,084 $ 56.97 Granted 230,750 56.95 Cancelled — — Vested (175,235 ) 52.71 Unvested at March 31, 2016 273,599 $ 59.68
Schedule of Stock Options Valuation Assumptions	The grant-date fair value of the Company’s stock options is estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the three months ended March 31, 2016 and year ended December 31, 2015: March 31, 2016 December 31, 2015 Weighted average grant-date fair value of options $ 19.57 $ 21.78 Risk-free interest rate 1.4 % 1.5 % Expected volatility 33 % 35 % Expected life (in years) 5.5 5.5

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities	The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 9.0% and 9.5% Revenue Bonds and contingent consideration liabilities as of March 31, 2016 and December 31, 2015 were as follows (in thousands): Carrying Amount Fair Value March 31, December 31, March 31, December 31, Amended and Restated Senior Credit Facility $ 2,079,958 $ 1,135,861 $ 2,079,958 $ 1,135,861 6.125% Senior Notes due 2021 $ 147,202 $ 147,082 $ 152,354 $ 149,288 5.125% Senior Notes due 2022 $ 294,919 $ 294,749 $ 297,868 $ 275,590 5.625% Senior Notes due 2023 $ 639,672 $ 639,431 $ 653,767 $ 604,262 6.500% Senior Notes due 2024 $ 381,528 $ — $ 396,789 $ — 9.0% and 9.5% Revenue Bonds $ 23,514 $ 23,621 $ 23,514 $ 23,621 Contingent consideration liabilities $ 667 $ 667 $ 667 $ 667

Current Assets (Tables)

Current Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Other current assets consisted of the following (in thousands): March 31, December 31, Prepaid expenses $ 29,397 $ 21,817 Other receivables 22,877 17,518 Insurance receivable – current portion 5,290 5,290 Workers’ compensation deposits – current portion 7,500 7,500 Income taxes receivable 6,676 6,540 Inventory 4,779 4,681 Other 3,284 3,549 Other current assets $ 79,803 $ 66,895

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2016
Other Liabilities Disclosure [Abstract]
Summary of Other Accrued Liabilities	Other accrued liabilities consisted of the following (in thousands): March 31, December 31, Unearned income $ 24,608 $ 446 Accrued interest 15,868 26,132 Insurance liability – current portion 10,490 10,490 Other current liabilities 8,797 7,499 Income taxes payable 4,039 7,367 Accrued property taxes 2,829 2,951 Other 42,032 17,921 Other accrued liabilities $ 108,663 $ 72,806

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2016
Summary of Reconciliation of Segment EBITDA to Income from Continuing Operations	The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands): Three Months Ended March 31, 2016 2015 Revenue: U.S. Facilities $ 408,264 $ 290,507 U.K. Facilities 206,975 73,315 Corporate and Other 1,574 1,961 $ 616,813 $ 365,783 Segment EBITDA (1): U.S. Facilities $ 106,840 $ 76,364 U.K. Facilities 44,931 18,811 Corporate and Other (20,759 ) (16,463 ) $ 131,012 $ 78,712 Three Months Ended March 31, 2016 2015 Segment EBITDA (1) $ 131,012 $ 78,712 Plus (less): Equity-based compensation expense (6,956 ) (3,894 ) Gain on foreign currency derivatives 410 53 Transaction-related expenses (26,298 ) (18,416 ) Interest expense, net (37,714 ) (22,146 ) Depreciation and amortization (27,975 ) (13,104 ) Income from continuing operations before income taxes $ 32,479 $ 21,205
Summary of Assets by Operating Segment	March 31, 2016 December 31, 2015 Assets (2): U.S. Facilities $ 3,138,727 $ 3,061,519 U.K. Facilities 3,390,950 1,045,922 Corporate and Other 166,682 171,767 $ 6,696,359 $ 4,279,208 (2) Assets include property and equipment for the U.S. Facilities of $885.2 million, U.K. Facilities of $2.4 billion and corporate and other of $42.8 million at March 31, 2016. Assets include property and equipment for the U.S. Facilities of $832.2 million, U.K. Facilities of $824.4 million and corporate and other of $52.4 million at December 31, 2015.
Goodwill [Member]
Summary of Assets by Operating Segment	U.S. Facilities U.K. Facilities Corporate Consolidated Goodwill: Balance at January 1, 2016 $ 1,941,873 $ 186,342 $ — $ 2,128,215 Increase from 2016 acquisitions — 652,146 — 652,146 Foreign currency translation loss — (11,406 ) — (11,406 ) Other 2,371 39 — 2,410 Balance at March 31, 2016 $ 1,944,244 $ 827,121 $ — $ 2,771,365

Financial Information for the37

Financial Information for the Company and Its Subsidiaries (Tables)	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Condensed Consolidating Balance Sheets	Acadia Healthcare Company, Inc. Condensed Consolidating Balance Sheets March 31, 2016 (In thousands) Parent Combined Combined Consolidating Total Current assets: Cash and cash equivalents $ — $ 17,069 $ 19,513 $ — $ 36,582 Accounts receivable, net — 200,870 76,010 — 276,880 Other current assets — 65,826 20,879 (6,902 ) 79,803 Total current assets — 283,765 116,402 (6,902 ) 393,265 Property and equipment, net — 848,951 2,488,814 — 3,337,765 Goodwill — 1,837,710 933,655 — 2,771,365 Intangible assets, net — 57,059 45,534 — 102,593 Deferred tax assets – noncurrent 3,946 32,981 4,826 — 41,753 Investment in subsidiaries 5,266,912 — — (5,266,912 ) — Other assets 849,968 36,606 10,029 (846,985 ) 49,618 Total assets $ 6,120,826 $ 3,097,072 $ 3,599,260 $ (6,120,799 ) $ 6,696,359 Current liabilities: Current portion of long-term debt $ 68,988 $ — $ 235 $ — $ 69,223 Accounts payable — 75,861 42,349 — 118,210 Accrued salaries and benefits — 72,272 40,442 — 112,714 Other accrued liabilities 14,678 — 100,887 (6,902 ) 108,663 Total current liabilities 83,666 148,133 183,913 (6,902 ) 408,810 Long-term debt 3,474,290 — 870,264 (846,985 ) 3,497,569 Deferred tax liabilities – noncurrent — — 94,882 — 94,882 Other liabilities — 78,979 45,513 — 124,492 Total liabilities 3,557,956 227,112 1,194,572 (853,887 ) 4,125,753 Redeemable noncontrolling interests — — 7,736 — 7,736 Total equity 2,562,870 2,869,960 2,396,952 (5,266,912 ) 2,562,870 Total liabilities and equity $ 6,120,826 $ 3,097,072 $ 3,599,260 $ (6,120,799 ) $ 6,696,359 Acadia Healthcare Company, Inc. Condensed Consolidating Balance Sheets December 31, 2015 (In thousands) Parent Combined Combined Consolidating Total Current assets: Cash and cash equivalents $ — $ 1,987 $ 9,228 $ — $ 11,215 Accounts receivable, net — 187,546 29,080 — 216,626 Other current assets — 57,968 8,927 — 66,895 Total current assets — 247,501 47,235 — 294,736 Property and equipment, net — 805,439 903,614 — 1,709,053 Goodwill — 1,835,339 292,876 — 2,128,215 Intangible assets, net — 57,024 2,551 — 59,575 Deferred tax assets – noncurrent 3,946 40,587 4,581 — 49,114 Investment in subsidiaries 3,495,067 — — (3,495,067 ) — Other assets 427,270 32,947 2,322 (424,024 ) 38,515 Total assets $ 3,926,283 $ 3,018,837 $ 1,253,179 $ (3,919,091 ) $ 4,279,208 Current liabilities: Current portion of long-term debt $ 45,125 $ — $ 235 $ — $ 45,360 Accounts payable — 75,015 16,326 — 91,341 Accrued salaries and benefits — 66,249 14,447 — 80,696 Other accrued liabilities 26,132 10,886 35,788 — 72,806 Total current liabilities 71,257 152,150 66,796 — 290,203 Long-term debt 2,171,998 — 447,410 (424,024 ) 2,195,384 Deferred tax liabilities – noncurrent — — 23,936 — 23,936 Other liabilities — 75,159 3,443 — 78,602 Total liabilities 2,243,255 227,309 541,585 (424,024 ) 2,588,125 Redeemable noncontrolling interests — — 8,055 — 8,055 Total equity 1,683,028 2,791,528 703,539 (3,495,067 ) 1,683,028 Total liabilities and equity $ 3,926,283 $ 3,018,837 $ 1,253,179 $ (3,919,091 ) $ 4,279,208
Summary of Condensed Consolidating Statement of Comprehensive Income (Loss)	Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Comprehensive Income (Loss) Three Months Ended March 31, 2016 (In thousands) Parent Combined Combined Consolidating Total Revenue before provision for doubtful accounts $ — $ 402,934 $ 224,249 $ — $ 627,183 Provision for doubtful accounts — (9,342 ) (1,028 ) — (10,370 ) Revenue — 393,592 223,221 — 616,813 Salaries, wages and benefits 6,956 211,033 123,039 — 341,028 Professional fees — 22,677 17,314 — 39,991 Supplies — 18,462 8,223 — 26,685 Rents and leases — 8,577 6,229 — 14,806 Other operating expenses — 48,849 21,398 — 70,247 Depreciation and amortization — 12,751 15,224 — 27,975 Interest expense, net 13,433 16,093 8,188 — 37,714 Gain on foreign currency derivatives (410 ) — — — (410 ) Transaction-related expenses — 21,435 4,863 — 26,298 Total expenses 19,979 359,877 204,478 — 584,334 (Loss) income from continuing operations before income taxes (19,979 ) 33,715 18,743 — 32,479 Equity in earnings of subsidiaries 40,869 — — (40,869 ) — (Benefit from) provision for income taxes (4,479 ) 7,407 4,182 — 7,110 Income (loss) from continuing operations 25,369 26,308 14,561 (40,869 ) 25,369 Income from discontinued operations, net of income taxes — — — — — Net income (loss) 25,369 26,308 14,561 (40,869 ) 25,369 Net loss attributable to noncontrolling interests — — 319 — 319 Net income (loss) attributable to Acadia Healthcare $ 25,369 $ 26,308 $ 14,880 $ (40,869 ) $ 25,688 Other comprehensive loss: Foreign currency translation loss — — (48,415 ) — (48,415 ) Other comprehensive loss — — (48,415 ) — (48,415 ) Comprehensive income (loss) $ 25,369 $ 26,308 $ (33,535 ) $ (40,869 ) $ (22,727 ) Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Comprehensive Income (Loss) Three Months Ended March 31, 2015 (In thousands) Parent Combined Combined Consolidating Total Revenue before provision for doubtful accounts $ — $ 287,765 $ 86,393 $ — $ 374,158 Provision for doubtful accounts — (7,419 ) (956 ) — (8,375 ) Revenue — 280,346 85,437 — 365,783 Salaries, wages and benefits 3,894 155,699 46,278 — 205,871 Professional fees — 16,485 5,942 — 22,427 Supplies — 13,009 3,245 — 16,254 Rents and leases — 5,117 769 — 5,886 Other operating expenses — 25,115 15,412 — 40,527 Depreciation and amortization — 8,711 4,393 — 13,104 Interest expense, net 12,948 5,721 3,477 — 22,146 Gain on foreign currency derivatives (53 ) — — — (53 ) Transaction-related expenses — 18,416 — — 18,416 Total expenses 16,789 248,273 79,516 — 344,578 (Loss) income from continuing operations before income taxes (16,789 ) 32,073 5,921 — 21,205 Equity in earnings of subsidiaries 25,987 — — (25,987 ) — (Benefit from) provision for income taxes (5,396 ) 10,497 1,512 — 6,613 Income (loss) from continuing operations 14,594 21,576 4,409 (25,987 ) 14,592 Income from discontinued operations, net of income taxes — 2 — — 2 Net income (loss) $ 14,594 $ 21,578 $ 4,409 $ (25,987 ) $ 14,594 Other comprehensive loss: Foreign currency translation loss — — (29,389 ) — (29,389 ) Other comprehensive loss — — (29,389 ) — (29,389 ) Comprehensive income (loss) $ 14,594 $ 21,578 $ (24,980 ) $ (25,987 ) $ (14,795 )
Summary of Condensed Consolidating Statement of Cash Flows	Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Cash Flows Three Months Ended March 31, 2016 (In thousands) Parent Combined Combined Consolidating Total Operating activities: Net income (loss) $ 25,369 $ 26,308 $ 14,561 $ (40,869 ) $ 25,369 Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities: Equity in earnings of subsidiaries (40,869 ) — — 40,869 — Depreciation and amortization — 12,751 15,224 — 27,975 Amortization of debt issuance costs 2,254 — (107 ) — 2,147 Equity-based compensation expense 6,956 — — — 6,956 Deferred income tax (benefit) expense — 8,846 239 — 9,085 Gain on foreign currency derivatives (410 ) — — — (410 ) Other — 896 (14 ) — 882 Change in operating assets and liabilities, net of effect of acquisitions: Accounts receivable, net — (13,560 ) 9,811 — (3,749 ) Other current assets — (3,596 ) (4,479 ) — (8,075 ) Other assets — (1,992 ) (410 ) — (2,402 ) Accounts payable and other accrued liabilities — 7,564 (66 ) — 7,498 Accrued salaries and benefits — 6,388 (12,735 ) — (6,347 ) Other liabilities — 4,416 (4,062 ) — 354 Net cash (used in) provided by continuing operating activities (6,700 ) 48,021 17,962 — 59,283 Net cash used in discontinued operating activities — (619 ) — — (619 ) Net cash (used in) provided by operating activities (6,700 ) 47,402 17,962 — 58,664 Investing activities: Cash paid for acquisitions, net of cash acquired — — (580,096 ) — (580,096 ) Cash paid for capital expenditures — (64,272 ) (25,817 ) — (90,089 ) Cash paid for real estate acquisitions — (2,998 ) (11,801 ) — (14,799 ) Settlement of foreign currency derivatives — 745 — — 745 Other — (1,208 ) — — (1,208 ) Net cash used in investing activities — (67,733 ) (617,714 ) — (685,447 ) Financing activities: Borrowings on long-term debt 1,480,000 — — — 1,480,000 Borrowings on revolving credit facility 58,000 — — — 58,000 Principal payments on revolving credit facility (166,000 ) — — — (166,000 ) Principal payments on long-term debt (13,669 ) — — — (13,669 ) Repayment of assumed debt (1,348,389 ) — — — (1,348,389 ) Payment of debt issuance costs (34,167 ) — — — (34,167 ) Issuance of common stock 685,097 — — — 685,097 Common stock withheld for minimum statutory taxes, net (6,679 ) — — — (6,679 ) Excess tax benefit from equity awards — — — — — Other — (224 ) — — (224 ) Cash (used in) provided by intercompany activity (647,493 ) 35,637 611,856 — — Net cash provided by financing activities 6,700 35,413 611,856 — 653,969 Effect of exchange rate changes on cash — — (1,819 ) — (1,819 ) Net increase in cash and cash equivalents — 15,082 10,285 — 25,367 Cash and cash equivalents at beginning of the period — 1,987 9,228 — 11,215 Cash and cash equivalents at end of the period $ — $ 17,069 $ 19,513 $ — $ 36,582 Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Cash Flows Three Months Ended March 31, 2015 (In thousands) Parent Combined Combined Consolidating Total Operating activities: Net income (loss) $ 14,594 $ 21,578 $ 4,409 $ (25,987 ) $ 14,594 Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities: Equity in earnings of subsidiaries (25,987 ) — — 25,987 — Depreciation and amortization — 8,711 4,393 — 13,104 Amortization of debt issuance costs 1,578 — (110 ) — 1,468 Equity-based compensation expense 3,894 — — — 3,894 Deferred income tax (benefit) expense 646 18,354 224 — 19,224 Loss from discontinued operations, net of taxes — (2 ) — — (2 ) Gain on foreign currency derivatives (53 ) — — — (53 ) Other — 364 14 — 378 Change in operating assets and liabilities, net of effect of acquisitions: — Accounts receivable, net — (8,265 ) 1,308 — (6,957 ) Other current assets — (24,182 ) 424 — (23,758 ) Other assets — (638 ) 2 — (636 ) Accounts payable and other accrued liabilities — 6,645 (5,371 ) — 1,274 Accrued salaries and benefits — (4,440 ) (582 ) — (5,022 ) Other liabilities — 762 (182 ) — 580 Net cash (used in) provided by continuing operating activities (5,328 ) 18,887 4,529 — 18,088 Net cash provided by discontinued operating activities — 134 — — 134 Net cash (used in) provided by operating activities (5,328 ) 19,021 4,529 — 18,222 Investing activities: Cash paid for acquisitions, net of cash acquired — (48,317 ) (1,301 ) — (49,618 ) Cash paid for capital expenditures — (41,426 ) (11,453 ) — (52,879 ) Cash paid for real estate acquisitions — (1,722 ) — — (1,722 ) Other — (383 ) — — (383 ) Net cash used in investing activities — (91,848 ) (12,754 ) — (104,602 ) Financing activities: Borrowings on long-term debt 875,000 — — — 875,000 Borrowings on revolving credit facility 93,000 — — — 93,000 Principal payments on long-term debt (7,938 ) — — — (7,938 ) Repayment of assumed debt (904,467 ) — — — (904,467 ) Payment of debt issuance costs (22,191 ) — — — (22,191 ) Common stock withheld for minimum statutory taxes, net (5,110 ) — — — (5,110 ) Excess tax benefit from equity awards 4,310 — — — 4,310 Cash (used in) provided by intercompany activity (27,276 ) 10,964 16,312 — — Net cash provided by financing activities 5,328 10,964 16,312 — 32,604 Effect of exchange rate changes on cash — — (2,232 ) — (2,232 ) Net (decrease) increase in cash and cash equivalents — (61,863 ) 5,855 — (56,008 ) Cash and cash equivalents at beginning of the period — 76,685 17,355 — 94,040 Cash and cash equivalents at end of the period $ — $ 14,822 $ 23,210 $ — $ 38,032

Description of Business and B38

Description of Business and Basis of Presentation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016BedsStateFacilities
Accounting Policies [Abstract]
Number of facilities | Facilities	585
Number of beds | Beds	17,400
Number of operating states | State	39

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations	$ 25,688	$ 14,592
Income from discontinued operations		2
Net income attributable to Acadia Healthcare Company, Inc.	$ 25,688	$ 14,594
Denominator:
Weighted average shares outstanding for basic earnings per share	82,943	62,530
Effect of dilutive instruments	477	364
Shares used in computing diluted earnings per common share	83,420	62,894
Basic earnings per share:
Income from continuing operations	$ 0.31	$ 0.23
Income from discontinued operations	0	0
Net income	0.31	0.23
Diluted earnings per share:
Income from continuing operations	0.31	0.23
Income from discontinued operations	0	0
Net income	$ 0.31	$ 0.23

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	0.8	0.9

Acquisitions - Priory Acquisiti

Acquisitions - Priory Acquisition - Additional Information (Detail) - Priory [Member] $ in Billions	Feb. 16, 2016USD ($)BedFacilityshares
Business Acquisition [Line Items]
Total consideration related to acquisition	$ 2.2
Business acquisition cash paid	$ 1.9
Shares issued for acquisition | shares	4,033,561
Number of facilities acquired | Facility	324
Number of beds | Bed	7,100

Acquisitions - 2015 US Acquisit

Acquisitions - 2015 US Acquisitions - Additional Information (Detail) $ in Millions	Dec. 01, 2015USD ($)BedsFacility	Nov. 01, 2015USD ($)BedsStateCenter	Jul. 01, 2015USD ($)Beds	Mar. 01, 2015USD ($)Center	Feb. 11, 2015USD ($)BedsStateCenterFacilitiesshares	Mar. 31, 2016State	Aug. 31, 2015USD ($)
Business Acquisition [Line Items]
Number of operating states | State						39
MMO Behavioral Health Systems [Member]
Business Acquisition [Line Items]
Number of beds | Beds	80
Business acquisition cash paid	$ 20.2
Number of facilities acquired | Facility	2
Discovery House-Group Inc [Member]
Business Acquisition [Line Items]
Business acquisition cash paid		$ 118.5
Number of facilities acquired | Center		19
Number of operating states | State		4
Duffys Napa Valley Rehab [Member]
Business Acquisition [Line Items]
Number of beds | Beds		61
Business acquisition cash paid		$ 29.6
Quality Addiction Management [Member]
Business Acquisition [Line Items]
Business acquisition cash paid				$ 54.8
Number of facilities acquired | Center				7
CRC Health Group, Inc [Member]
Business Acquisition [Line Items]
Number of facilities acquired | Center					81
Number of operating states | State					30
Total consideration related to acquisition					$ 1,300
Shares issued for acquisition | shares					5,975,326
Outstanding indebtedness of CRC repaid					$ 904.5
Number of inpatient facilities | Facilities					35
CRC Health Group, Inc [Member] | Minimum [Member]
Business Acquisition [Line Items]
Number of beds | Beds					2,400
Massachusetts [Member] | Southcoast Behavioral [Member]
Business Acquisition [Line Items]
Approximate value of noncontrolling interest							$ 9.2
Equity ownership interests percentage in the facility							75.00%
Percentage of noncontrolling interests in the facility							25.00%
Pennsylvania [Member] | Belmont Behavioral Health [Member]
Business Acquisition [Line Items]
Number of beds | Beds			147
Business acquisition cash paid			$ 39.5
Total consideration related to acquisition			35
Estimated working capital settlement			$ 4.5

Acquisitions - 2015 UK Acquisit

Acquisitions - 2015 UK Acquisitions - Additional Information (Detail) - United Kingdom [Member] $ in Millions	Nov. 01, 2015USD ($)Beds	Oct. 01, 2015USD ($)Beds	Sep. 01, 2015USD ($)BedsFacility	Jul. 01, 2015USD ($)Beds	Jun. 01, 2015USD ($)BedsFacility	Apr. 01, 2015USD ($)BedsFacility
Care UK Limited [Member]
Business Acquisition [Line Items]
Business acquisition cash paid | $					$ 88.2
Number of beds | Beds					299
Number of facilities acquired | Facility					15
Choice Lifestyles [Member]
Business Acquisition [Line Items]
Business acquisition cash paid | $					$ 25.9	$ 37.5
Number of beds | Beds					42	48
Number of facilities acquired | Facility					1	2
Pastoral Care Group [Member]
Business Acquisition [Line Items]
Business acquisition cash paid | $						$ 34.2
Number of beds | Beds						65
Number of facilities acquired | Facility						2
Mildmay Oaks [Member]
Business Acquisition [Line Items]
Business acquisition cash paid | $						$ 14.9
Number of beds | Beds						67
Cleveland House [Member]
Business Acquisition [Line Items]
Business acquisition cash paid | $	$ 10.3
Number of beds | Beds	32
Meadow View [Member]
Business Acquisition [Line Items]
Business acquisition cash paid | $		$ 6.8
Number of beds | Beds		28
Health and Social Care Partnerships [Member]
Business Acquisition [Line Items]
Business acquisition cash paid | $			$ 26.2
Number of beds | Beds			50
Number of facilities acquired | Facility			2
The Danshell Group [Member]
Business Acquisition [Line Items]
Business acquisition cash paid | $			$ 59.8
Number of beds | Beds			73
Number of facilities acquired | Facility			3
Manor Hall [Member]
Business Acquisition [Line Items]
Business acquisition cash paid | $			$ 14
Number of beds | Beds			26
The Manor Clinic [Member]
Business Acquisition [Line Items]
Business acquisition cash paid | $				$ 5.9
Number of beds | Beds				15

Acquisitions - Summary of Acqui

Acquisitions - Summary of Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Business Acquisition [Line Items]
Goodwill associated with domestic acquisitions	$ 2,771,365	$ 2,128,215
Domestic Acquisitions in 2015 and 2014 [Member]
Business Acquisition [Line Items]
Goodwill associated with domestic acquisitions	$ 282,700		$ 282,700

Acquisitions - Priory Acquisi45

Acquisitions - Priory Acquisition (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Feb. 16, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 2,771,365		$ 2,128,215
Priory [Member]
Business Acquisition [Line Items]
Cash		$ 10,253
Accounts receivable		57,831
Prepaid expenses and other current assets		7,920
Property and equipment		1,603,307
Goodwill		652,146
Intangible assets		43,394
Other assets		7,760
Total assets acquired		2,382,611
Accounts payable		24,203
Accrued salaries and benefits		39,588
Other accrued expenses		46,806
Deferred tax liabilities - noncurrent		71,233
Debt		1,348,389
Other liabilities		45,161
Total liabilities assumed		1,575,380
Net assets acquired		$ 807,231

Acquisitions - Summary of Acq46

Acquisitions - Summary of Acquisitions (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 2,771,365	$ 2,128,215
2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		25,016
Accounts receivable		74,094
Prepaid expenses and other current assets		29,683
Property and equipment		409,306
Goodwill		1,358,611
Intangible assets		37,204
Deferred tax assets-noncurrent		74,383
Other assets		6,529
Total assets acquired		2,014,826
Accounts payable		9,305
Accrued salaries and benefits		18,148
Other accrued expenses		44,164
Deferred tax liabilities - noncurrent		13,541
Debt		904,467
Other liabilities		34,730
Total liabilities assumed		1,024,355
Redeemable noncontrolling interests		9,132
Net assets acquired		981,339
Other [Member] | 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		5,417
Accounts receivable		27,059
Prepaid expenses and other current assets		2,738
Property and equipment		273,143
Goodwill		315,010
Intangible assets		204
Other assets		51
Total assets acquired		623,622
Accounts payable		4,564
Accrued salaries and benefits		3,321
Other accrued expenses		5,291
Deferred tax liabilities - noncurrent		13,541
Other liabilities		10
Total liabilities assumed		26,727
Redeemable noncontrolling interests		9,132
Net assets acquired		587,763
CRC Health Group, Inc [Member] | 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		19,599
Accounts receivable		47,035
Prepaid expenses and other current assets		26,945
Property and equipment		136,163
Goodwill		1,043,601
Intangible assets		37,000
Deferred tax assets-noncurrent		74,383
Other assets		6,478
Total assets acquired		1,391,204
Accounts payable		4,741
Accrued salaries and benefits		14,827
Other accrued expenses		38,873
Debt		904,467
Other liabilities		34,720
Total liabilities assumed		997,628
Net assets acquired		$ 393,576

Acquisitions - Other (Detail)

Acquisitions - Other (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Business Combinations [Abstract]
Advisory and financing commitment fees	$ 14,850	$ 10,337
Legal, accounting and other costs	11,448	3,819
Severance and contract termination costs		4,260
Transaction-related expenses	$ 26,298	$ 18,416

Acquisitions - Pro Forma Inform

Acquisitions - Pro Forma Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Business Acquisition [Line Items]
Revenue	$ 616,813	$ 365,783
Income from continuing operations before income taxes	32,479	21,205
Acquisitions 2015 and 2016 [Member]
Business Acquisition [Line Items]
Revenue	294,600
Income from continuing operations before income taxes	$ 47,600
Acquisitions 2015 [Member]
Business Acquisition [Line Items]
Revenue		68,600
Income from continuing operations before income taxes		$ 15,000

Acquisitions - Pro Forma Info49

Acquisitions - Pro Forma Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Business Combinations [Abstract]
Revenue	$ 725,667	$ 685,480
Income from continuing operations, before income taxes	$ 12,363	$ 14,779

Other Intangible Assets - Other

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	$ 3,347	$ 3,347
Intangible assets not subject to amortization, Gross Carrying Amount	102,348	59,225
Total	105,695	62,572
Intangible assets subject to amortization, Accumulated Amortization	(3,102)	(2,997)
Contract Intangible Assets [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	2,100	2,100
Intangible assets subject to amortization, Accumulated Amortization	(1,855)	(1,750)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,247	1,247
Intangible assets subject to amortization, Accumulated Amortization	(1,247)	(1,247)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	11,463	11,479
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	80,799	37,800
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	$ 10,086	$ 9,946

Other Intangible Assets - Addit

Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Amortization expense	$ 0.1	$ 0.1
Estimated amortization expense, remainder of 2016	0.4
Estimated amortization expense, 2017	0
Estimated amortization expense, 2018	0
Estimated amortization expense, 2019	0
Estimated amortization expense, 2020	0
Trade Names [Member] | Priory [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Fair value of intangible assets acquired	$ 43.4

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,488,383	$ 1,828,523
Less accumulated depreciation	(150,618)	(119,470)
Property and equipment, net	3,337,765	1,709,053
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	838,181	214,138
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,118,535	1,277,800
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	361,703	141,543
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 169,964	$ 195,042

Long-Term Debt - Components of

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Sep. 21, 2015
Debt Instrument [Line Items]
Less: unamortized debt issuance costs, discount and premium	$ (67,699)	$ (35,416)
Long-term debt	3,566,792	2,240,744
Long-term debt	3,566,792	2,240,744
Less: current portion	(69,223)	(45,360)
Long-term debt	3,497,569	2,195,384
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Senior Notes	150,000	150,000
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Senior Notes	300,000	300,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes	650,000	650,000	$ 650,000
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Senior Notes	390,000
Amended and Restated Senior Credit Facility [Member] | Senior Secured Term A Loans [Member]
Debt Instrument [Line Items]
Senior Secured	625,719	500,750
Amended and Restated Senior Credit Facility [Member] | Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Senior Secured	1,446,362	495,000
Amended and Restated Senior Credit Facility [Member] | Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Senior Secured	50,000	158,000
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 22,410	$ 22,410

Long-Term Debt - Components o54

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Feb. 16, 2016	Feb. 11, 2016	Sep. 21, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
Senior notes maturity year	2,021	2,021
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
Senior notes maturity year	2,022	2,022
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
Senior notes maturity year	2,023	2,023
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%		6.50%
Senior notes maturity year	2,024
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.00%	9.00%
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.50%	9.50%

Long-Term Debt (Amended and Res

Long-Term Debt (Amended and Restated Senior Credit Facility) - Additional Information (Detail) - Amended and Restated Senior Credit Facility [Member] - USD ($)

Feb. 16, 2016

Dec. 15, 2015

Dec. 31, 2012

Apr. 01, 2011

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Feb. 11, 2015

Feb. 06, 2015

Dec. 15, 2014

Debt Instrument [Line Items]

Date entered into an agreement

Dec. 31, 2012

Apr. 1, 2011

Additional term loans

$ 135,000,000

Amount available under revolving line of credit

$ 241,500,000

Term loan principal repayments

$ 10,000,000

Debt instrument maturity date

Feb. 13, 2019

Feb. 11, 2022

Term loan repayments

$ 1,300,000

Consolidated funded debt, unrestricted and unencumbered cash to consolidated EBITDA

$ 40,000,000

Senior Secured Revolving Line of Credit [Member]

Debt Instrument [Line Items]

Line of credit

300,000,000

Seventh Amendment [Member]

Debt Instrument [Line Items]

Date entered into an agreement

Feb. 6, 2015

TLB Facility Due on February 16, 2023 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,400,000

Ninth Amendment [Member]

Debt Instrument [Line Items]

Date entered into an agreement

Jan. 25, 2016

Restrictive covenants on investments, Description

The Ninth Amendment modifies certain definitions and provides increased flexibility to the Company in terms of its financial covenants. The Company’s baskets for permitted investments were also increased to provide increased flexibility for it to invest in non-wholly owned subsidiaries, joint ventures and foreign subsidiaries. The Company may now invest in non-wholly owned subsidiaries and joint ventures up to 10.0% of the Company and its subsidiaries’ total assets in any four consecutive fiscal quarter period, and up to 12.5% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The Company may also invest in foreign subsidiaries that are not loan parties up to 10% of the Company and its subsidiaries’ total assets in any consecutive four fiscal quarter period, and up to 15% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The foregoing permitted investments are subject to an aggregate cap of 25% of the Company and its subsidiaries’ total assets in any fiscal year.

Second Incremental Amendment [Member]

Debt Instrument [Line Items]

Date entered into an agreement

Feb. 16, 2016

New incremental Term Loan B facility

$ 955,000,000

Letter of Credit [Member] | Seventh Amendment [Member]

Debt Instrument [Line Items]

Line of credit

$ 20,000,000

Swing Line Sublimit [Member] | Seventh Amendment [Member]

Debt Instrument [Line Items]

Line of credit

$ 20,000,000

Eurodollar [Member]

Debt Instrument [Line Items]

Interest on borrowings

3.25%

Basis spread on variable rate

1.00%

Base Rate Loans [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.25%

Basis spread on variable rate

0.50%

London Interbank Offered Rate (LIBOR) [Member]

Debt Instrument [Line Items]

Interest on borrowings

3.25%

Senior Debt Obligations [Member] | First Incremental Amendment [Member]

Debt Instrument [Line Items]

Date entered into an agreement

Feb. 11, 2015

Line of credit

$ 500,000,000

September 30, 2015 to December 31, 2015 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 1,300,000

September 30, 2015 to December 31, 2015 [Member] | TLB Facility Due on February 16, 2023 [Member] | Scenario, Forecast [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,400,000

June 30, 2016 to December 31, 2016 [Member]

Debt Instrument [Line Items]

Term loan principal repayments

$ 12,600,000

Term loan repayments

$ 1,300,000

June 30, 2016 to December 31, 2016 [Member] | TLB Facility Due on February 16, 2023 [Member] | Scenario, Forecast [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,400,000

March 31, 2017 to December 31, 2017 [Member]

Debt Instrument [Line Items]

Term loan principal repayments

16,800,000

Term loan repayments

$ 1,300,000

March 31, 2017 to December 31, 2017 [Member] | TLB Facility Due on February 16, 2023 [Member] | Scenario, Forecast [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,400,000

March 31, 2018 to December 31, 2018 [Member]

Debt Instrument [Line Items]

Term loan principal repayments

$ 20,900,000

Long-Term Debt (6.125% Senior N

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($) $ in Millions	Mar. 12, 2013	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Issued Senior Notes	$ 150
Debt instrument interest rate	6.125%	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		Payable semi-annually in arrears on March 15 and September 15 of each year.

Long-Term Debt (5.125% Senior N

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes Due 2022 [Member] - USD ($) $ in Millions	Jul. 01, 2014	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Issued Senior Notes	$ 300
Debt instrument interest rate	5.125%	5.125%	5.125%
Debt instrument maturity date	Jul. 1, 2022
Interest on the notes		Payable semi-annually in arrears on January 1 and July 1 of each year.

Long-Term Debt (5.625% Senior N

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Feb. 11, 2016	Dec. 31, 2015	Sep. 21, 2015
Debt Instrument [Line Items]
Issued Senior Notes		$ 375,000		$ 275,000
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Debt instrument maturity date	Feb. 15, 2023
Senior Notes	$ 650,000		$ 650,000	$ 650,000

Long-Term Debt (6.500% Senior N

Long-Term Debt (6.500% Senior Notes due 2024) - Additional Information (Detail) - 6.500% Senior Notes Due 2024 [Member] - USD ($)	Feb. 16, 2016	Mar. 31, 2016
Debt Instrument [Line Items]
Issued Senior Notes	$ 390,000,000
Debt instrument interest rate	6.50%	6.50%
Debt instrument maturity date	Mar. 1, 2024
Interest on the notes		Payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

Long-Term Debt (9.0% and 9.5% R

Long-Term Debt (9.0% and 9.5% Revenue Bonds) - Additional Information (Detail) - USD ($) $ in Thousands	Nov. 11, 2012	Mar. 31, 2016	Dec. 31, 2015
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds		$ 22,410	$ 22,410
9.0% and 9.5% Revenue Bonds [Member] | Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 23,000
Debt service reserve fund within other assets		$ 2,300	$ 2,300
Debt instrument premium	2,600
9.0% and 9.5% Revenue Bonds [Member] | Fair Value Measurement [Member] | Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	25,600
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		9.00%	9.00%
9.0% Revenue Bonds [Member] | Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 7,500
Debt instrument interest rate	9.00%
Debt instrument maturity date	Dec. 1, 2030
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		9.50%	9.50%
9.5% Revenue Bonds [Member] | Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 15,500
Debt instrument interest rate	9.50%
Debt instrument maturity date	Dec. 1, 2040

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Feb. 16, 2016	Jan. 12, 2016	May. 11, 2015	Feb. 11, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 03, 2016	Dec. 31, 2015
Equity [Line Items]
Common stock, shares authorized					180,000,000		180,000,000	90,000,000
Common stock offered		11,500,000	5,175,000		86,539,997			70,745,746
Common stock offer price		$ 61	$ 66.50		$ 0.01			$ 0.01
Underwriting discount amount		$ 15,800	$ 12,000
Additional offering-related costs		700	800
Net proceeds from sale of shares		$ 685,000	$ 331,300		$ 216,882	$ 380,210
CRC Health Group, Inc [Member]
Equity [Line Items]
Total consideration related to acquisition				$ 1,300,000
Shares issued for acquisition				5,975,326
Priory [Member]
Equity [Line Items]
Total consideration related to acquisition	$ 2,200,000
Shares issued for acquisition	4,033,561
Business acquisition cash paid	$ 1,900,000

Equity-Based Compensation - Add

Equity-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	4,700,000
Equity incentive plan available for future grant	1,336,703
Annual increments in employee grants	25.00%
Stock options, contractual term	10 years
Equity-based compensation expense	$ 6,956,000	$ 3,894,000
Unrecognized compensation expense related to unvested options	$ 65,700,000
Vesting period	1 year 6 months
Deferred income tax benefit	$ 9,085,000	19,224,000
Tax realized from stock options exercised	0	4,300,000
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ (2,800,000)	$ (1,600,000)

Equity-Based Compensation - Sto

Equity-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options outstanding, Beginning balance	694,743	737,422
Options granted	294,350	204,700
Options exercised	(7,075)	(214,079)
Options cancelled	(16,775)	(33,300)
Options outstanding, Ending balance	965,243	694,743	737,422
Options outstanding, Weighted Average Exercise Price, Beginning balance	$ 42.87	$ 32.19
Options exercisable, Ending balance	323,979	106,330
Options granted, Weighted Average Exercise Price	$ 59.72	$ 63.07
Options exercised, Weighted Average Exercise Price	32	42.75
Options cancelled, Weighted Average Exercise Price	57.99	46.53
Options outstanding, Weighted Average Exercise Price, Ending balance	$ 47.86	$ 42.87	$ 32.19
Options outstanding, Aggregate Intrinsic Value, Beginning balance	$ 20,717	$ 14,512
Options exercisable, Weighted Average Exercise Price, Ending balance	$ 40.58	$ 36.41
Options granted, Aggregate Intrinsic Value		$ 1,724
Options granted, Weighted Average Remaining Contractual Term	9 years 10 months 10 days	9 years 2 months 16 days
Options exercised, Aggregate Intrinsic Value	$ 278	$ 9,890
Options outstanding, Weighted Average Remaining Contractual Term	8 years 2 months 12 days	7 years 8 months 12 days	8 years 1 month 2 days
Options cancelled, Aggregate Intrinsic Value	$ 0	$ 0
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	6 years 9 months 4 days	5 years 9 months 29 days
Options outstanding, Aggregate Intrinsic Value, Ending balance	$ 11,884	$ 20,717	$ 14,512
Options exercisable, Aggregate Intrinsic Value, Ending balance	$ 8,527	$ 4,968

Equity-Based Compensation - Res

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	944,562	722,028
Granted, Number of Shares	188,587	503,052
Cancelled, Number of Shares	(32,050)	(44,900)
Vested, Number of Shares	(213,787)	(235,618)
Unvested, Number of Shares/Units, Ending balance	887,312	944,562
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 52.74	$ 39.77
Granted, Weighted Average Grant-Date Fair Value	59.72	62.67
Cancelled, Weighted Average Grant-Date Fair Value	59.79	49.55
Vested, Weighted Average Grant-Date Fair Value	47.18	34.93
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 55.30	$ 52.74

Equity-Based Compensation - R65

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	218,084	125,113
Granted, Number of Units	230,750	217,994
Cancelled, Number of Units	0	0
Vested, Number of Units	(175,235)	(125,023)
Unvested, Number of Shares/Units, Ending balance	273,599	218,084
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 56.97	$ 38.73
Granted, Weighted Average Grant-Date Fair Value	56.95	61.77
Cancelled, Weighted Average Grant-Date Fair Value	0	0
Vested, Weighted Average Grant-Date Fair Value	52.71	32.38
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 59.68	$ 56.97

Equity-Based Compensation - Sch

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant-date fair value of options	$ 19.57	$ 21.78
Risk-free interest rate	1.40%	1.50%
Expected volatility	33.00%	35.00%
Expected life (in years)	5 years 6 months	5 years 6 months

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Effective tax rates	21.90%	31.20%

Derivatives - Additional Inform

Derivatives - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Gains associated with changes in fair value of the foreign currency forward contracts	$ 0.4	$ 0.1

Fair Value Measurements - Carry

Fair Value Measurements - Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration liabilities	$ 667	$ 667
Fair Value [Member] | Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	2,079,958	1,135,861
Fair Value [Member] | 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	152,354	149,288
Fair Value [Member] | 5.125% Senior Notes Due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	297,868	275,590
Fair Value [Member] | 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	653,767	604,262
Fair Value [Member] | 6.500% Senior Notes Due 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	396,789
Fair Value [Member] | 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	23,514	23,621
Carrying Amounts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration liabilities	667	667
Carrying Amounts [Member] | Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	2,079,958	1,135,861
Carrying Amounts [Member] | 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	147,202	147,082
Carrying Amounts [Member] | 5.125% Senior Notes Due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	294,919	294,749
Carrying Amounts [Member] | 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	639,672	639,431
Carrying Amounts [Member] | 6.500% Senior Notes Due 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	381,528
Carrying Amounts [Member] | 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	$ 23,514	$ 23,621

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	Mar. 31, 2016	Feb. 16, 2016	Dec. 31, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	6.125%		6.125%		6.125%
5.125% Senior Notes Due 2022 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	5.125%		5.125%	5.125%
5.625 % Senior Notes Due 2021 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	5.625%
6.500% Senior Notes Due 2024 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	6.50%	6.50%
9.0% Revenue Bonds [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	9.00%		9.00%
9.5% Revenue Bonds [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	9.50%		9.50%

Current Assets - Other Current

Current Assets - Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 29,397	$ 21,817
Other receivables	22,877	17,518
Insurance receivable - current portion	5,290	5,290
Workers' compensation deposits - current portion	7,500	7,500
Income taxes receivable	6,676	6,540
Inventory	4,779	4,681
Other	3,284	3,549
Other current assets	$ 79,803	$ 66,895

Other Accrued Liabilities - Sum

Other Accrued Liabilities - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Accounts Payable and Accrued Liabilities, Current [Abstract]
Unearned income	$ 24,608	$ 446
Accrued interest	15,868	26,132
Insurance liability - current portion	10,490	10,490
Other current liabilities	8,797	7,499
Income taxes payable	4,039	7,367
Accrued property taxes	2,829	2,951
Other	42,032	17,921
Other accrued liabilities	$ 108,663	$ 72,806

Segment Information - Additiona

Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016BedsStateFacilities
Segment Reporting Information [Line Items]
Number of facilities | Facilities	585
Number of beds | Beds	17,400
Number of operating states | State	39
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities | Facilities	205
Number of beds | Beds	8,000
Number of operating states | State	39
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities | Facilities	380
Number of beds | Beds	9,400

Segment Information - Summary o

Segment Information - Summary of Financial Information by Operating Segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Revenue	$ 616,813	$ 365,783
Segment EBITDA	131,012	78,712
Equity-based compensation expense	(6,956)	(3,894)
Gain on foreign currency derivatives	410	53
Transaction-related expenses	(26,298)	(18,416)
Interest expense, net	(37,714)	(22,146)
Depreciation and amortization	(27,975)	(13,104)
Income from continuing operations before income taxes	32,479	21,205
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	408,264	290,507
Segment EBITDA	106,840	76,364
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	206,975	73,315
Segment EBITDA	44,931	18,811
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Revenue	1,574	1,961
Segment EBITDA	$ (20,759)	$ (16,463)

Segment Information - Summary75

Segment Information - Summary of Financial Information by Operating Segment, Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Goodwill:
Beginning balance	$ 2,128,215
Increase from 2016 acquisitions	652,146
Foreign currency translation loss	(11,406)
Other	2,410
Ending balance	2,771,365
U.S. Facilities [Member]
Goodwill:
Beginning balance	1,941,873
Other	2,371
Ending balance	1,944,244
U.K. Facilities [Member]
Goodwill:
Beginning balance	186,342
Increase from 2016 acquisitions	652,146
Foreign currency translation loss	(11,406)
Other	39
Ending balance	$ 827,121

Segment Information - Summary76

Segment Information - Summary of Financial Information by Operating Segment, Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Assets:
Assets	$ 6,696,359	$ 4,279,208
U.S. Facilities [Member]
Assets:
Assets	3,138,727	3,061,519
U.K. Facilities [Member]
Assets:
Assets	3,390,950	1,045,922
Corporate and Other [Member]
Assets:
Assets	$ 166,682	$ 171,767

Segment Information - Summary77

Segment Information - Summary of Financial Information by Operating Segment, Assets (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 3,337,765	$ 1,709,053
U.S. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	885,200	832,200
U.K. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	2,400,000	824,400
Corporate and Other [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 42,800	$ 52,400

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Serenity Knolls Inc [Member] - Subsequent Event [Member] $ in Millions	Apr. 01, 2016USD ($)Beds
Subsequent Event [Line Items]
Number of beds | Beds	30
Business acquisition cash paid | $	$ 10

Financial Information for the79

Financial Information for the Company and Its Subsidiaries - Additional Information (Detail)	Mar. 31, 2016	Feb. 16, 2016	Feb. 11, 2016	Dec. 31, 2015	Sep. 21, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.125%			6.125%			6.125%
5.125% Senior Notes Due 2022 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.125%			5.125%		5.125%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%		5.625%	5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.50%	6.50%

Financial Information for the80

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 36,582	$ 11,215	$ 38,032	$ 94,040
Accounts receivable, net	276,880	216,626
Other current assets	79,803	66,895
Total current assets	393,265	294,736
Property and equipment, net	3,337,765	1,709,053
Goodwill	2,771,365	2,128,215
Intangible assets, net	102,593	59,575
Deferred tax assets - noncurrent	41,753	49,114
Other assets	49,618	38,515
Total assets	6,696,359	4,279,208
Current liabilities:
Current portion of long-term debt	69,223	45,360
Accounts payable	118,210	91,341
Accrued salaries and benefits	112,714	80,696
Other accrued liabilities	108,663	72,806
Total current liabilities	408,810	290,203
Long-term debt	3,497,569	2,195,384
Deferred tax liabilities - noncurrent	94,882	23,936
Other liabilities	124,492	78,602
Total liabilities	4,125,753	2,588,125
Redeemable noncontrolling interests	7,736	8,055
Total equity	2,562,870	1,683,028
Total liabilities and equity	6,696,359	4,279,208
Consolidating Adjustments [Member]
Current assets:
Other current assets	(6,902)
Total current assets	(6,902)
Investment in subsidiaries	(5,266,912)	(3,495,067)
Other assets	(846,985)	(424,024)
Total assets	(6,120,799)	(3,919,091)
Current liabilities:
Other accrued liabilities	(6,902)
Total current liabilities	(6,902)
Long-term debt	(846,985)	(424,024)
Total liabilities	(853,887)	(424,024)
Total equity	(5,266,912)	(3,495,067)
Total liabilities and equity	(6,120,799)	(3,919,091)
Parent [Member]
Current assets:
Deferred tax assets - noncurrent	3,946	3,946
Investment in subsidiaries	5,266,912	3,495,067
Other assets	849,968	427,270
Total assets	6,120,826	3,926,283
Current liabilities:
Current portion of long-term debt	68,988	45,125
Other accrued liabilities	14,678	26,132
Total current liabilities	83,666	71,257
Long-term debt	3,474,290	2,171,998
Total liabilities	3,557,956	2,243,255
Total equity	2,562,870	1,683,028
Total liabilities and equity	6,120,826	3,926,283
Combined Subsidiary Guarantors [Member]
Current assets:
Cash and cash equivalents	17,069	1,987	14,822	76,685
Accounts receivable, net	200,870	187,546
Other current assets	65,826	57,968
Total current assets	283,765	247,501
Property and equipment, net	848,951	805,439
Goodwill	1,837,710	1,835,339
Intangible assets, net	57,059	57,024
Deferred tax assets - noncurrent	32,981	40,587
Other assets	36,606	32,947
Total assets	3,097,072	3,018,837
Current liabilities:
Accounts payable	75,861	75,015
Accrued salaries and benefits	72,272	66,249
Other accrued liabilities		10,886
Total current liabilities	148,133	152,150
Other liabilities	78,979	75,159
Total liabilities	227,112	227,309
Total equity	2,869,960	2,791,528
Total liabilities and equity	3,097,072	3,018,837
Combined Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	19,513	9,228	$ 23,210	$ 17,355
Accounts receivable, net	76,010	29,080
Other current assets	20,879	8,927
Total current assets	116,402	47,235
Property and equipment, net	2,488,814	903,614
Goodwill	933,655	292,876
Intangible assets, net	45,534	2,551
Deferred tax assets - noncurrent	4,826	4,581
Other assets	10,029	2,322
Total assets	3,599,260	1,253,179
Current liabilities:
Current portion of long-term debt	235	235
Accounts payable	42,349	16,326
Accrued salaries and benefits	40,442	14,447
Other accrued liabilities	100,887	35,788
Total current liabilities	183,913	66,796
Long-term debt	870,264	447,410
Deferred tax liabilities - noncurrent	94,882	23,936
Other liabilities	45,513	3,443
Total liabilities	1,194,572	541,585
Redeemable noncontrolling interests	7,736	8,055
Total equity	2,396,952	703,539
Total liabilities and equity	$ 3,599,260	$ 1,253,179

Financial Information for the81

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	$ 627,183	$ 374,158
Provision for doubtful accounts	(10,370)	(8,375)
Revenue	616,813	365,783
Salaries, wages and benefits	341,028	205,871
Professional fees	39,991	22,427
Supplies	26,685	16,254
Rents and leases	14,806	5,886
Other operating expenses	70,247	40,527
Depreciation and amortization	27,975	13,104
Interest expense, net	37,714	22,146
Gain on foreign currency derivatives	(410)	(53)
Transaction-related expenses	26,298	18,416
Total expenses	584,334	344,578
(Loss) income from continuing operations before income taxes	32,479	21,205
(Benefit from) provision for income taxes	7,110	6,613
Income (loss) from continuing operations	25,369	14,592
Income from discontinued operations, net of income taxes		2
Net income (loss)	25,369	14,594
Net loss attributable to noncontrolling interests	319
Net income (loss) attributable to Acadia Healthcare Company, Inc.	25,688	14,594
Other comprehensive loss:
Foreign currency translation loss	(48,415)	(29,389)
Other comprehensive loss	(48,415)	(29,389)
Comprehensive loss attributable to Acadia Healthcare Company. Inc.	(22,727)	(14,795)
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in earnings of subsidiaries	(40,869)	(25,987)
Income (loss) from continuing operations	(40,869)	(25,987)
Net income (loss)	(40,869)	(25,987)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	(40,869)
Other comprehensive loss:
Comprehensive loss attributable to Acadia Healthcare Company. Inc.	(40,869)	(25,987)
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Salaries, wages and benefits	6,956	3,894
Interest expense, net	13,433	12,948
Gain on foreign currency derivatives	(410)	(53)
Total expenses	19,979	16,789
(Loss) income from continuing operations before income taxes	(19,979)	(16,789)
Equity in earnings of subsidiaries	40,869	25,987
(Benefit from) provision for income taxes	(4,479)	(5,396)
Income (loss) from continuing operations	25,369	14,594
Net income (loss)	25,369	14,594
Net income (loss) attributable to Acadia Healthcare Company, Inc.	25,369
Other comprehensive loss:
Comprehensive loss attributable to Acadia Healthcare Company. Inc.	25,369	14,594
Combined Subsidiary Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	402,934	287,765
Provision for doubtful accounts	(9,342)	(7,419)
Revenue	393,592	280,346
Salaries, wages and benefits	211,033	155,699
Professional fees	22,677	16,485
Supplies	18,462	13,009
Rents and leases	8,577	5,117
Other operating expenses	48,849	25,115
Depreciation and amortization	12,751	8,711
Interest expense, net	16,093	5,721
Transaction-related expenses	21,435	18,416
Total expenses	359,877	248,273
(Loss) income from continuing operations before income taxes	33,715	32,073
(Benefit from) provision for income taxes	7,407	10,497
Income (loss) from continuing operations	26,308	21,576
Income from discontinued operations, net of income taxes		2
Net income (loss)	26,308	21,578
Net income (loss) attributable to Acadia Healthcare Company, Inc.	26,308
Other comprehensive loss:
Comprehensive loss attributable to Acadia Healthcare Company. Inc.	26,308	21,578
Combined Non-Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	224,249	86,393
Provision for doubtful accounts	(1,028)	(956)
Revenue	223,221	85,437
Salaries, wages and benefits	123,039	46,278
Professional fees	17,314	5,942
Supplies	8,223	3,245
Rents and leases	6,229	769
Other operating expenses	21,398	15,412
Depreciation and amortization	15,224	4,393
Interest expense, net	8,188	3,477
Transaction-related expenses	4,863
Total expenses	204,478	79,516
(Loss) income from continuing operations before income taxes	18,743	5,921
(Benefit from) provision for income taxes	4,182	1,512
Income (loss) from continuing operations	14,561	4,409
Net income (loss)	14,561	4,409
Net loss attributable to noncontrolling interests	319
Net income (loss) attributable to Acadia Healthcare Company, Inc.	14,880
Other comprehensive loss:
Foreign currency translation loss	(48,415)	(29,389)
Other comprehensive loss	(48,415)	(29,389)
Comprehensive loss attributable to Acadia Healthcare Company. Inc.	$ (33,535)	$ (24,980)

Financial Information for the82

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities:
Net income (loss)	$ 25,369	$ 14,594
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	27,975	13,104
Amortization of debt issuance costs	2,147	1,468
Equity-based compensation expense	6,956	3,894
Deferred income tax (benefit) expense	9,085	19,224
Loss from discontinued operations, net of taxes		(2)
Gain on foreign currency derivatives	(410)	(53)
Other	882	378
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	(3,749)	(6,957)
Other current assets	(8,075)	(23,758)
Other assets	(2,402)	(636)
Accounts payable and other accrued liabilities	7,498	1,274
Accrued salaries and benefits	(6,347)	(5,022)
Other liabilities	354	580
Net cash (used in) provided by continuing operating activities	59,283	18,088
Net cash provided by discontinued operating activities	(619)	134
Net cash (used in) provided by operating activities	58,664	18,222
Investing activities:
Cash paid for acquisitions, net of cash acquired	(580,096)	(49,618)
Cash paid for capital expenditures	(90,089)	(52,879)
Cash paid for real estate acquisitions	(14,799)	(1,722)
Settlement of foreign currency derivatives	745
Other	(1,208)	(383)
Net cash used in investing activities	(685,447)	(104,602)
Financing activities:
Borrowings on long-term debt	1,480,000	875,000
Borrowings on revolving credit facility	58,000	93,000
Principal payments on revolving credit facility	(166,000)
Principal payments on long-term debt	(13,669)	(7,938)
Repayment of assumed debt	(1,348,389)	(904,467)
Payment of debt issuance costs	(34,167)	(22,191)
Issuance of common stock	685,097
Common stock withheld for minimum statutory taxes, net	(6,679)	(5,110)
Excess tax benefit from equity awards		4,310
Other	(224)
Net cash provided by financing activities	653,969	32,604
Effect of exchange rate changes on cash	(1,819)	(2,232)
Net (decrease) increase in cash and cash equivalents	25,367	(56,008)
Cash and cash equivalents at beginning of the period	11,215	94,040
Cash and cash equivalents at end of the period	36,582	38,032
Consolidating Adjustments [Member]
Operating activities:
Net income (loss)	(40,869)	(25,987)
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries	40,869	25,987
Parent [Member]
Operating activities:
Net income (loss)	25,369	14,594
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries	(40,869)	(25,987)
Amortization of debt issuance costs	2,254	1,578
Equity-based compensation expense	6,956	3,894
Deferred income tax (benefit) expense		646
Gain on foreign currency derivatives	(410)	(53)
Change in operating assets and liabilities, net of effect of acquisitions:
Net cash (used in) provided by continuing operating activities	(6,700)	(5,328)
Net cash (used in) provided by operating activities	(6,700)	(5,328)
Financing activities:
Borrowings on long-term debt	1,480,000	875,000
Borrowings on revolving credit facility	58,000	93,000
Principal payments on revolving credit facility	(166,000)
Principal payments on long-term debt	(13,669)	(7,938)
Repayment of assumed debt	(1,348,389)	(904,467)
Payment of debt issuance costs	(34,167)	(22,191)
Issuance of common stock	685,097
Common stock withheld for minimum statutory taxes, net	(6,679)	(5,110)
Excess tax benefit from equity awards		4,310
Cash (used in) provided by intercompany activity	(647,493)	(27,276)
Net cash provided by financing activities	6,700	5,328
Combined Subsidiary Guarantors [Member]
Operating activities:
Net income (loss)	26,308	21,578
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	12,751	8,711
Deferred income tax (benefit) expense	8,846	18,354
Loss from discontinued operations, net of taxes		(2)
Other	896	364
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	(13,560)	(8,265)
Other current assets	(3,596)	(24,182)
Other assets	(1,992)	(638)
Accounts payable and other accrued liabilities	7,564	6,645
Accrued salaries and benefits	6,388	(4,440)
Other liabilities	4,416	762
Net cash (used in) provided by continuing operating activities	48,021	18,887
Net cash provided by discontinued operating activities	(619)	134
Net cash (used in) provided by operating activities	47,402	19,021
Investing activities:
Cash paid for acquisitions, net of cash acquired		(48,317)
Cash paid for capital expenditures	(64,272)	(41,426)
Cash paid for real estate acquisitions	(2,998)	(1,722)
Settlement of foreign currency derivatives	745
Other	(1,208)	(383)
Net cash used in investing activities	(67,733)	(91,848)
Financing activities:
Other	(224)
Cash (used in) provided by intercompany activity	35,637	10,964
Net cash provided by financing activities	35,413	10,964
Net (decrease) increase in cash and cash equivalents	15,082	(61,863)
Cash and cash equivalents at beginning of the period	1,987	76,685
Cash and cash equivalents at end of the period	17,069	14,822
Combined Non-Guarantors [Member]
Operating activities:
Net income (loss)	14,561	4,409
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	15,224	4,393
Amortization of debt issuance costs	(107)	(110)
Deferred income tax (benefit) expense	239	224
Other	(14)	14
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	9,811	1,308
Other current assets	(4,479)	424
Other assets	(410)	2
Accounts payable and other accrued liabilities	(66)	(5,371)
Accrued salaries and benefits	(12,735)	(582)
Other liabilities	(4,062)	(182)
Net cash (used in) provided by continuing operating activities	17,962	4,529
Net cash (used in) provided by operating activities	17,962	4,529
Investing activities:
Cash paid for acquisitions, net of cash acquired	(580,096)	(1,301)
Cash paid for capital expenditures	(25,817)	(11,453)
Cash paid for real estate acquisitions	(11,801)
Net cash used in investing activities	(617,714)	(12,754)
Financing activities:
Cash (used in) provided by intercompany activity	611,856	16,312
Net cash provided by financing activities	611,856	16,312
Effect of exchange rate changes on cash	(1,819)	(2,232)
Net (decrease) increase in cash and cash equivalents	10,285	5,855
Cash and cash equivalents at beginning of the period	9,228	17,355
Cash and cash equivalents at end of the period	$ 19,513	$ 23,210